



Review article

Methanobrevibacter smithii cell variants in human physiology and pathology: A review

Ihab Malat^{a,b}, Michel Drancourt^{a,b}, Ghiles Grine^{a,b,*}^a IHU Méditerranée Infection, Marseille, France^b Aix-Marseille-Université, MEPHI, IHU Méditerranée Infection, France

ARTICLE INFO

Keywords:

*Methanobrevibacter smithii**Methanobrevibacter*

Methanogens

Methane

Archaea

Nanoarchaea

Candidatus Nanopusillus phoceensis

Microbiota

ABSTRACT

Methanobrevibacter smithii (*M. smithii*), initially isolated from human feces, has been recognised as a distinct taxon within the Archaea domain following comprehensive phenotypic, genetic, and genomic analyses confirming its uniqueness among methanogens. Its diversity, encompassing 15 genotypes, mirrors that of biotic and host-associated ecosystems in which *M. smithii* plays a crucial role in detoxifying hydrogen from bacterial fermentations, converting it into mechanically expelled gaseous methane. In microbiota in contact with host epithelial mucosae, *M. smithii* centres metabolism-driven microbial networks with *Bacteroides*, *Prevotella*, *Ruminococcus*, *Veillonella*, *Enterococcus*, *Escherichia*, *Enterobacter*, *Klebsiella*, whereas symbiotic association with the nanoarchaea *Candidatus* Nanopusillus phoceensis determines small and large cell variants of *M. smithii*. The former translocate with bacteria to induce detectable inflammatory and serological responses and are co-cultured from blood, urine, and tissular abscesses with bacteria, prototyping *M. smithii* as a model organism for pathogenicity by association. The sources, mechanisms and dynamics of *in utero* and lifespan *M. smithii* acquisition, its diversity, and its susceptibility to molecules of environmental, veterinary, and medical interest still have to be deeply investigated, as only four strains of *M. smithii* are available in microbial collections, despite the pivotal role this neglected microorganism plays in microbiota physiology and pathologies.

1. Introduction

Forty years ago, Blach and Wolfe successfully isolated a methanogenic archaea (herein referred to as methanogen) initially named “*Methanobrevibacter ruminantium* PS strain” from sludge [1]. This strain, later identified as *Methanobrevibacter smithii* (*M. smithii*) PS strain, was subsequently cultured from faecal samples obtained from four apparently healthy individuals under anaerobic conditions and observed using fluorescence microscopy [2]. These breakthroughs were followed by the indirect detection of *M. smithii* in the human digestive tract by measuring methane (CH₄) [3,4]. An enumeration method indicated that *M. smithii* was the most abundant methanogen in human feces [5] and was virtually present in 95.7 % of apparently healthy individuals [6]. Its certified absence in feces has been observed only in young patients suffering from life-threatening acute malnutrition [7]. Later observations underlined the key role of *M. smithii* in gut microbiota homeostasis, while further clinical studies implicated *M. smithii* in three lines of pathologies, including dysbiosis, abscesses, and archaeemia (its presence in the blood) [8–10].

Over 40 years of cumulative reports related to *M. smithii* in mucosae-associated microbiota physiology and pathology, including

* Corresponding author. IHU Méditerranée Infection, Marseille, France.

E-mail address: grineghiles@gmail.com (G. Grine).

notable contributions from our group of research to this field, incited us to comprehensively review data regarding the clinical microbiology of *M. smithii* in complex microbial networks. This work recently centred on symbiotic *Candidatus* Nanopusillus phoenicensis, which may determine small and large cell variants exhibiting differential capabilities to act as opportunistic pathogens, always associated with bacteria.

1.1. Bibliography strategy

This review was based on the scientific literature published up to September 2023 available in Medline via PubMed (<https://pubmed.ncbi.nlm.nih.gov/>) and Google Scholar databases. To describe *M. smithii* and its presence in animals, the environment, and humans, the following query was generated and searched for in titles and abstracts: (“*Methanobrevibacter smithii*”) AND (“Human” OR “Microbiota” OR “Environments” OR “Environment” OR “Environmental” OR “Sewer” OR “Sediments” OR “Sea” OR “Marine” OR “River” OR “Water” OR “Wastewater” OR “Waste” OR “Wastes” OR “Biomass” OR “Soil” OR “Soils” OR “Coal” OR “Bioreactor” OR “Reactors” OR “Plant” OR “Plants” OR “Rhizosphere” OR “Anaerobic digestion” OR “Halophile” OR “Halophilic” OR “Thermophilic” OR “Extremophile” OR “Extremophilic” OR “Rumen methanogens” OR “animals” OR “millipedes” OR “pigs” OR “Rumen” OR “Ruminants” OR “livestock” OR “protozoa” OR “Food” OR “Foodstuffs”). The initial screening of articles involved evaluating titles and abstracts against specific inclusion and exclusion criteria. To be included, articles had to meet certain conditions, such as being original research articles published in English and specifically addressing the detection and isolation of *M. smithii* in the context of human, animal, and environmental studies. Conversely, articles were excluded if they were published in languages other than English or if they were repetitions of previously included articles. Following the initial selection, the complete texts of chosen articles were thoroughly examined to gather pertinent information. Additionally, a manual search was conducted by exploring the references cited in the previously selected papers, aiming to identify and include any relevant articles that might contribute to the overall understanding of the subject. A total of 252 articles were retrieved from PubMed and 6260 articles from Google Scholar. After selection steps, based on titles and abstracts, exclusion of duplications, selection of original papers only written in English language, 166 papers were included in this review.

2. Bibliometry

According to the search results in the PubMed database, the first publication regarding *M. smithii* was in 1981 and publications have gradually increased since then up to 252. By means of control, this can be compared to work on *Staphylococcus aureus*, which showed a huge number of related papers ($n = 63\,899$) (Supplementary Fig. S1). Accordingly, 95 genomes were available in GenBank (<https://www.ncbi.nlm.nih.gov/genome>) at September 2023, comprising in detail 34 genomes derived from *M. smithii* isolates and 61 genomes derived from metagenome-assembled genomes (MAGs). Moreover, only four genome sequences were complete, 22 at scaffold assembly level and 69 at contig level. In total, 76/95 (80 %) genomes derived *M. smithii* from the human digestive tract, especially the gut, while four extra-digestive tract *M. smithii* genomes (all made in our laboratory) included two human blood isolates, one brain abscess isolate, and one breast milk isolates. Fifteen extra-human genomes included ten genomes derived from pig guts, two from the digestive system of mice, two from monkey guts, and one reference ATCC 35061 genome from an anthropic sewage digester (Table 1).

3. Antiquity of *M. smithii* in human microbiota

Metagenomic studies detected *M. smithii* ancient DNA (aDNA) in 2/161 (1.24 %) human dental roots which were between 2223 and 3023 years old and one human dental calculus between 13 780 and 14 180 years old, collected from archaeological sites located in Maslomecz and Niemcza, both in Poland, and San Teodoro in Italy [11,12]. More recently, genomic investigations of eight human palaeofaeces which were older than 1000 years, derived from Boomerang Shelter (Utah, USA), the Arid West Cave (in Southwest USA, precise location unknown) and Zape (La Cueva de los Muertos Chiquitos, Mexico), yielded 181 MAGs, including two ancient *M. smithii* genomes from two Boomerang Shelter samples representative of two ancient *M. smithii* lineages which may have diverged around 85 000 years ago [13]. These data traced *M. smithii* as an ancient companion of the human digestive tract, suggesting its relative insusceptibility to environmental and population changes over such extensive spatial and temporal ranges (Fig. 1).

4. Sources for *M. smithii* microbiota colonisation

Little is known about the sources of *M. smithii* and its dynamics along the digestive tract during the human lifespan. In this paper, we review the environmental ecosystems of newborns, children and adults in whom *M. smithii* has been detected, which could constitute sources of contamination during the lifetime of the individuals.

4.1. Abiotic environment

The close connection between *M. smithii* and human faecal matter, demonstrated by its detection through PCR amplification in human sewage samples, has led to *M. smithii* being proposed as a biomarker for faecal contamination of recreational waters, rivers, beaches, and even rain water [14–23]. For example, water samples collected from Arroyo Burro (AB) ($n = 6$) and Mission Creek (MC) ($n = 8$) in Santa Barbara, California, and investigated using the *M. smithii* *nifH* gene standard PCR revealed four positive samples (AB: 1/6; MC: 3/8) and three positive samples (AB: 1/6; MC: 2/8) during the dry and wet weather seasons, respectively [18]. Of 21

Table 1

Summary of 95 *M. smithii* genomes available in Genbank till September 2023. The variant type, source, assembly accession, sequencing method, assembly level, genome length, number of coding sequences (CDS), number of CRISPR, coding ratio, GC%, and number of sequences were shown for each genome. (<https://www.ncbi.nlm.nih.gov/genome/>; <https://dfast.dbbj.nig.ac.jp/dfc/>).

| <i>M. smithii</i> species | Variant type | Source | Assembly accession |
|--------------------------------------|--------------|------------------------|--------------------|
| ATCC 35061; PS; DSMZ 861 | strain | Sewage digester | GCA_000016525.1 |
| KB11 | strain | Human gut | GCA_002813085.1 |
| CE91-St68 | strain | Human gut | GCA_022846175.1 |
| CE91-St67 | strain | Human gut | GCA_022846155.1 |
| DSM 2375 | strain | Human gut | GCA_000151245.1 |
| DSM 2374 | strain | Human gut | GCA_000151225.1 |
| CAG:186 | Metagenomics | Human gut | GCA_000437055.1 |
| MGYG-HGUT-02163 | isolate | Human gut | GCA_902384055.1 |
| PRJEB30652 | isolate | Human blood | GCA_900654205.1 |
| L1_008_000M1 | Metagenomics | Human gut | GCA_018379875.1 |
| MCC662 | strain | Human gut | GCA_018784305.1 |
| B73_50.fa | Metagenomics | Human gut | GCA_021641085.1 |
| MTG248_bin.32.fa | Metagenomics | Human gut | GCA_934879315.1 |
| MTG240_bin.3.fa | Metagenomics | Human gut | GCA_934882215.1 |
| MTG237_bin.37.fa | Metagenomics | Human gut | GCA_934854605.1 |
| MTG238_bin.31.fa | Metagenomics | Human gut | GCA_934882835.1 |
| MTG233_bin.9.fa | Metagenomics | Human gut | GCA_934841515.1 |
| MTG232_bin.10.fa | Metagenomics | Human gut | GCA_934834405.1 |
| MTG239_bin.1.fa | Metagenomics | Human gut | GCA_934882635.1 |
| MTG246_bin.5.fa | Metagenomics | Human gut | GCA_934876175.1 |
| MTG247_bin.44.fa | Metagenomics | Human gut | GCA_934881615.1 |
| MTG235_bin.19.fa | Metagenomics | Human gut | GCA_934864325.1 |
| MTG236_bin.38.fa | Metagenomics | Human gut | GCA_934864615.1 |
| MTG234_bin.2.fa | Metagenomics | Human gut | GCA_934836805.1 |
| S25M_St_metabat_50 | Metagenomics | Monkey gut | GCA_030539805.1 |
| S8M_St_25 | Metagenomics | Monkey gut | GCA_030539535.1 |
| TS145A | strain | Human gut | GCA_000189795.2 |
| TS145B | strain | Human gut | GCA_000189815.2 |
| TS146A | strain | Human gut | GCA_000189835.2 |
| TS146B | strain | Human gut | GCA_000189855.2 |
| TS146C | strain | Human gut | GCA_000189875.2 |
| TS146D | strain | Human gut | GCA_000189895.2 |
| TS146E | strain | Human gut | GCA_000189915.2 |
| TS147A | strain | Human gut | GCA_000189935.2 |
| TS147B | strain | Human gut | GCA_000189955.2 |
| TS147C | strain | Human gut | GCA_000189975.2 |
| TS94A | strain | Human gut | GCA_000189995.2 |
| TS94B | strain | Human gut | GCA_000190015.2 |
| TS94C | strain | Human gut | GCA_000190035.2 |
| TS95A | strain | Human gut | GCA_000190055.2 |
| TS95B | strain | Human gut | GCA_000190075.2 |
| TS95C | strain | Human gut | GCA_000190095.2 |
| TS95D | strain | Human gut | GCA_000190115.2 |
| TS96A | strain | Human gut | GCA_000190135.2 |
| TS96B | strain | Human gut | GCA_000190155.2 |
| TS96C | strain | Human gut | GCA_000190175.2 |
| ACE6 | strain | Human brain abscess | GCA_000824705.1 |
| WWM1085 | strain | Human gut | GCA_002252585.1 |
| C2_CSUR_P5816 | strain | Women breast milk | GCA_900650605.1 |
| MGYG-HGUT-02446 | isolate | Human gut | GCA_902387325.1 |
| PRJEB32190 | isolate | Human blood | GCA_901111125.1 |
| COPD437 | Metagenomics | Human gut | GCA_014871915.1 |
| MAG004 | Metagenomics | Pig gut | GCA_016294185.1 |
| ERR260234-bin.14 | Metagenomics | Human gut | GCA_905209735.1 |
| SRR413754-bin.38 | Metagenomics | Human gut | GCA_905207865.1 |
| ERR1297821-bin.15 | Metagenomics | Human gut | GCA_905206215.1 |
| min17_bin38 | Metagenomics | Human gut | GCA_928722215.1 |
| SUG1019 | Metagenomics | Pig gut | GCA_022784485.1 |
| SRR14474043_bin.15_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945607175.1 |
| SRR15732360_bin.19_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945868565.1 |
| ERR1855546_bin.25_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945864075.1 |
| SRR15057922_bin.11_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945928295.1 |
| SRR17382103_bin.13_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945873965.1 |
| SRR14812344_bin.14_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_946407825.1 |
| SRR5240748_bin.9_metaWRAP_v1.3_MAG | Metagenomics | Pig gut | GCA_945830685.1 |
| SRR19721633_bin.21_metawrap_v1.3_MAG | Metagenomics | Mouse digestive system | GCA_947002465.1 |

(continued on next page)

Table 1 (continued)

| M. smithii species | Variant type | Source | Assembly accession |
|--------------------------------------|--------------|------------------------|--------------------|
| VEG01_HAM_0019 | Metagenomics | Human gut | GCA_025992465.1 |
| VEG01_HIC_0070 | Metagenomics | Human gut | GCA_025992335.1 |
| SRR7721896_bin.58_CONCOCT_v1.1_MAG | Metagenomics | Human gut | GCA_938021325.1 |
| ERR688525_bin.5_CONCOCT_v1.1_MAG | Metagenomics | Human gut | GCA_938044845.1 |
| SRR17622767_bin.81_metawrap_v1.3_MAG | Metagenomics | Mouse digestive system | GCA_948471195.1 |
| SUG2190 | Metagenomics | Pig gut | GCA_028722865.1 |
| ERR9354249_bin.30_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958349965.1 |
| ERR8263739_bin.32_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958346845.1 |
| ERR9578286_bin.9_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958428575.1 |
| ERR9762707_bin.13_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958427485.1 |
| ERR9492527_bin.37_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958408655.1 |
| SRR18940298_bin.13_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958452655.1 |
| ERR9492520_bin.14_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958408285.1 |
| ERR9322428_bin.27_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958404925.1 |
| SRR18940299_bin.15_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958454305.1 |
| SRR17382081_bin.21_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958450395.1 |
| SRR22541668_bin.8_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958434505.1 |
| ERR8263824_bin.44_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958406505.1 |
| ERR9578260_bin.2_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958428305.1 |
| ERR9610937_bin.21_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958441245.1 |
| ERR9762677_bin.15_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_958367155.1 |
| SRR20881984_bin.37_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959026905.1 |
| SRR13494530_bin.17_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959022255.1 |
| SRR20881978_bin.12_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959018705.1 |
| SRR13494517_bin.23_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959026265.1 |
| SRR16280099_bin.15_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959603635.1 |
| SRR16244389_bin.33_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959605265.1 |
| SRR16244405_bin.3_MetaWRAP_v1.3_MAG | Metagenomics | Human gut | GCA_959596935.1 |
| N1173.2 | Metagenomics | Human gut | GCA_030841835.1 |

| Assembly level | Method | Genome length | Country | CDS |
|-----------------|--------|---------------|---------------------|------|
| Complete genome | WGS | 1853160 | United States | 1789 |
| Complete genome | WGS | 1805545 | South Korea | 1756 |
| Complete genome | WGS | 1791155 | Japan | 1716 |
| Complete genome | WGS | 1791153 | Japan | 1719 |
| Scaffolds | WGS | 1713248 | United States | 1679 |
| Scaffolds | WGS | 1729275 | United States | 1682 |
| Scaffolds | MAG | 1729973 | Denmark | 1707 |
| Scaffolds | WGS | 1729275 | United States | 1682 |
| Scaffolds | WGS | 1722603 | France | 1671 |
| Scaffolds | MAG | 1850699 | United States | 1767 |
| Scaffolds | WGS | 1785820 | Republic of Ireland | 1710 |
| Scaffolds | MAG | 1532323 | South Africa | 1338 |
| Scaffolds | MAG | 1715977 | Australia | 1690 |
| Scaffolds | MAG | 1701208 | Australia | 1682 |
| Scaffolds | MAG | 1733784 | Australia | 1697 |
| Scaffolds | MAG | 1713615 | Australia | 1680 |
| Scaffolds | MAG | 1732067 | Australia | 1692 |
| Scaffolds | MAG | 1735187 | Australia | 1693 |
| Scaffolds | MAG | 1738989 | Australia | 1693 |
| Scaffolds | MAG | 1647299 | Australia | 1647 |
| Scaffolds | MAG | 1672903 | Australia | 1650 |
| Scaffolds | MAG | 1725316 | Australia | 1680 |
| Scaffolds | MAG | 1708876 | Australia | 1692 |
| Scaffolds | MAG | 1690036 | Australia | 1587 |
| Scaffolds | MAG | 1749155 | Germany | 1754 |
| Scaffolds | MAG | 1472871 | Germany | 1406 |
| Contigs | WGS | 1782421 | United States | 1775 |
| Contigs | WGS | 1796940 | United States | 1863 |
| Contigs | WGS | 1791079 | United States | 1799 |
| Contigs | WGS | 1793406 | United States | 1803 |
| Contigs | WGS | 1947167 | United States | 2308 |
| Contigs | WGS | 1712884 | United States | 1673 |
| Contigs | WGS | 1951914 | United States | 1883 |
| Contigs | WGS | 2008849 | United States | 1958 |
| Contigs | WGS | 1964775 | United States | 1904 |
| Contigs | WGS | 1972568 | United States | 2022 |
| Contigs | WGS | 1888757 | United States | 1785 |
| Contigs | WGS | 1885844 | United States | 1823 |

(continued on next page)

Table 1 (continued)

| Assembly level | Method | Genome length | Country | CDS |
|----------------|--------|---------------|---------------|------|
| Contigs | WGS | 1910054 | United States | 1795 |
| Contigs | WGS | 1992013 | United States | 1954 |
| Contigs | WGS | 1972225 | United States | 1887 |
| Contigs | WGS | 1978848 | United States | 1865 |
| Contigs | WGS | 2011683 | United States | 1846 |
| Contigs | WGS | 1974662 | United States | 1842 |
| Contigs | WGS | 1869016 | United States | 1735 |
| Contigs | WGS | 1818091 | United States | 1735 |
| Contigs | WGS | 1718384 | France | 1644 |
| Contigs | WGS | 1926345 | United States | 1812 |
| Contigs | WGS | 1720664 | France | 1667 |
| Contigs | WGS | 1926345 | United States | 1812 |
| Contigs | WGS | 1712416 | France | 1660 |
| Contigs | MAG | 1837225 | Australia | |
| Contigs | MAG | 1590692 | China | 1546 |
| Contigs | MAG | 1807363 | Sweden | 1739 |
| Contigs | MAG | 1793403 | China | 1740 |
| Contigs | MAG | 2453823 | Netherlands | 1831 |
| Contigs | MAG | 1636575 | France | 1670 |
| Contigs | MAG | 1633763 | Canada | 1581 |
| Contigs | MAG | 1599471 | China | 1564 |
| Contigs | MAG | 1507832 | China | 1437 |
| Contigs | MAG | 1306612 | Germany | 1259 |
| Contigs | MAG | 1725827 | France | 1722 |
| Contigs | MAG | 1712501 | China | 1676 |
| Contigs | MAG | 1611557 | Canada | 1532 |
| Contigs | MAG | 1306612 | Germany | 1259 |
| Contigs | MAG | 1302826 | United States | 1161 |
| Contigs | MAG | 1792275 | South Korea | 1749 |
| Contigs | MAG | 1715912 | South Korea | 1663 |
| Contigs | MAG | 1721518 | China | 1699 |
| Contigs | MAG | 1929878 | Austria | 1810 |
| Contigs | MAG | 1877634 | Canada | 1818 |
| Contigs | MAG | 1191129 | Canada | 984 |
| Contigs | MAG | 1857507 | Denmark | 1866 |
| Contigs | MAG | 1607020 | Netherlands | 1557 |
| Contigs | MAG | 1863041 | Germany | 1819 |
| Contigs | MAG | 1787270 | Sweden | 1721 |
| Contigs | MAG | 1894993 | China | 1787 |
| Contigs | MAG | 1761494 | Italy | 1711 |
| Contigs | MAG | 1789153 | China | 1710 |
| Contigs | MAG | 1893122 | Denmark | 1799 |
| Contigs | MAG | 1792464 | Italy | 1738 |
| Contigs | MAG | 1550003 | India | 1402 |
| Contigs | MAG | 1639372 | China | 1525 |
| Contigs | MAG | 1673800 | Netherlands | 1484 |
| Contigs | MAG | 1560492 | Germany | 1352 |
| Contigs | MAG | 919190 | China | 774 |
| Contigs | MAG | 886946 | Sweden | 748 |
| Contigs | MAG | 1293539 | United States | 1176 |
| Contigs | MAG | 1191129 | Japan | 984 |
| Contigs | MAG | 1685532 | United States | 1639 |
| Contigs | MAG | 1191129 | Japan | 984 |
| Contigs | MAG | 1767959 | Mongolia | 1716 |
| Contigs | MAG | 1809816 | Malaysia | 1763 |
| Contigs | MAG | 1075103 | Malaysia | 823 |
| Contigs | MAG | 1792464 | United States | 1738 |

| Nb of CRISPR | Coding ratio % | GC% | Nb of sequences |
|--------------|----------------|------|-----------------|
| 2 | 90.2 | 31 | 1 |
| 1 | 89.5 | 31.2 | 1 |
| 1 | 89.8 | 31.1 | 1 |
| 1 | 89.9 | 31.1 | 1 |
| 1 | 88.9 | 31.3 | 9 |
| 1 | 89.5 | 31.3 | 10 |
| 0 | 88.3 | 31.2 | 30 |
| 1 | 89.5 | 31.3 | 10 |
| 1 | 89.8 | 31.2 | 14 |
| 2 | 86.1 | 31 | 22 |

(continued on next page)

Table 1 (continued)

| Nb of CRISPR | Coding ratio % | GC% | Nb of sequences |
|--------------|----------------|------|-----------------|
| 1 | 85.1 | 31.2 | 97 |
| 0 | 77 | 32 | 324 |
| 1 | 88.8 | 31.1 | 16 |
| 1 | 90.3 | 31.2 | 9 |
| 1 | 90.5 | 31.1 | 11 |
| 1 | 89.3 | 31.2 | 22 |
| 0 | 89.7 | 31.1 | 14 |
| 1 | 88.5 | 31.1 | 17 |
| 1 | 98.4 | 31.1 | 20 |
| 1 | 89.1 | 31.2 | 27 |
| 1 | 90 | 31.2 | 11 |
| 1 | 86.4 | 31.1 | 23 |
| 1 | 87.4 | 31.1 | 35 |
| 0 | 82.1 | 31.1 | 103 |
| 1 | 89.5 | 31.2 | 7 |
| 0 | 80.8 | 31.9 | 170 |
| 0 | 86.9 | 31.1 | 43 |
| 1 | 87.1 | 31.1 | 51 |
| 1 | 84.4 | 31.2 | 60 |
| 1 | 88.1 | 31.1 | 35 |
| 1 | 85.2 | 31.2 | 100 |
| 0 | 87.5 | 31.1 | 31 |
| 2 | 86.8 | 30.4 | 62 |
| 2 | 84.8 | 30.5 | 60 |
| 1 | 87 | 30.4 | 38 |
| 0 | 87.9 | 30.4 | 37 |
| 0 | 84.9 | 30.3 | 43 |
| 0 | 86.1 | 30.3 | 57 |
| 0 | 86.6 | 30.3 | 50 |
| 2 | 86.2 | 30.2 | 55 |
| 2 | 87.6 | 30.3 | 42 |
| 2 | 87.9 | 30.2 | 37 |
| 3 | 85.6 | 30.3 | 58 |
| 3 | 86.8 | 30.3 | 45 |
| 3 | 86.4 | 30.3 | 44 |
| 1 | 85.1 | 31.2 | 107 |
| 1 | 88.6 | 31.5 | 87 |
| 2 | 88.8 | 30.3 | 16 |
| 1 | 89.9 | 31.2 | 11 |
| 2 | 88.8 | 30.3 | 16 |
| 1 | 89.4 | 31.1 | 27 |
| 0 | | 31.2 | 35 |
| 0 | 87.2 | 31.5 | 49 |
| 2 | 87 | 30.5 | 36 |
| 2 | 89.9 | 31.1 | 29 |
| 1 | 44.8 | 31.7 | 1328 |
| 3 | 87.3 | 31.2 | 31 |
| 0 | 85.8 | 31.4 | 43 |
| 0 | 85.8 | 31.4 | 71 |
| 0 | 82.2 | 31.7 | 142 |
| 0 | 83 | 32.2 | 200 |
| 2 | 87.4 | 31.2 | 33 |
| 1 | 85.2 | 31.2 | 51 |
| 0 | 83.2 | 31.4 | 94 |
| 0 | 83 | 32.2 | 200 |
| 2 | 79.5 | 32 | 220 |
| 1 | 90 | 31.1 | 1 |
| 1 | 89.5 | 31.3 | 1 |
| 1 | 86.8 | 34 | 34 |
| 2 | 86.3 | 30.2 | 22 |
| 0 | 83.8 | 31.1 | 117 |
| 0 | 72.7 | 31.5 | 234 |
| 1 | 89.3 | 31.2 | 27 |
| 1 | 89.7 | 31.4 | 49 |
| 4 | 88.7 | 31.1 | 14 |
| 2 | 88.7 | 31 | 13 |
| 2 | 87.9 | 30.3 | 19 |
| 3 | 89.6 | 31.1 | 15 |
| 3 | 88 | 31 | 21 |

(continued on next page)

Table 1 (continued)

| Nb of CRISPR | Coding ratio % | GC% | Nb of sequences |
|--------------|----------------|------|-----------------|
| 2 | 86.1 | 30.3 | 38 |
| 2 | 87.8 | 31 | 20 |
| 0 | 77.6 | 31.2 | 136 |
| 2 | 80 | 31.4 | 158 |
| 1 | 78.9 | 30.8 | 194 |
| 1 | 72.9 | 30.3 | 209 |
| 0 | 68.1 | 31.7 | 203 |
| 0 | 66.6 | 31.5 | 197 |
| 0 | 80.3 | 31.6 | 199 |
| 0 | 72.7 | 31.5 | 234 |
| 0 | 89 | 31.3 | 64 |
| 0 | 72.7 | 31.5 | 234 |
| 3 | 89 | 31.1 | 24 |
| 3 | 90.1 | 31.1 | 16 |
| 0 | 63.2 | 30.9 | 253 |
| 2 | 87.8 | 31 | 20 |




Fig. 1. *Methanobrevibacter smithii* from antiquity to present. Two parts of *M. smithii* investigation from human samples (dental calculus, feces) were shown. Metagenomics studies succeeded to detect *M. smithii* DNA from ancient oral cavity and stool samples. Using genomics and culturomics approaches, first description and isolation of *M. smithii* was from human feces by Balch and Wolfe followed by several works about *M. smithii* enumeration in stools, microscopy observation, culture media development and genomic annotations.

environmental water samples collected from a Fitzgibbon (FG) stormwater drain, the Brisbane river (BR), Cabbage Tree Creek, Oxley Creek and Wivenhoe Dam in Australia, two samples derived from FG and BR were positive, using the same detection assay as above [20].

4.2. Animals

M. smithii inhabits the gastrointestinal tracts of various herbivore and ruminant mammals [24–28]. This archaeon plays a pivotal role in the digestive processes in these animals by aiding the breakdown of complex carbohydrates present in their diets [29]. In the stomach of ruminants, including cows and sheep, *M. smithii* thrives in the rumen, contributing to methane production during the fermentation of cellulose-rich plant material, later expelled by the animal through belching [30,31]. Similarly, *M. smithii* is found in the intestines of non-ruminant herbivores such as horses and rabbits, where it plays a comparable role in methane production during the digestion of fibrous plant material [27,32]. While essential for efficient energy extraction from cellulose-rich diets, methane generated by *M. smithii* and other methanogens in the digestive tract of animals also poses environmental challenges, due to its contribution to greenhouse gas emissions, preventing high atmosphere dissipation of energy from Earth [33,34]. As such, ongoing research seeks to balance the nutritional benefits of methanogens with strategies for methane reduction in livestock [35]. Accordingly, the study of *M. smithii* in animal models is pivotal to comprehending its role in the complex ecology of the gastrointestinal microbiome and its implications in health and disease. Rodent models, specifically germ-free and gnotobiotic mice, have been frequently used to identify *M. smithii* interactions with the host and other resident microbes [36–38]. Owing to their analogous anatomy and physiology to humans, pig models are also highly relevant, providing insights into the effects and interactions of *M. smithii* in the gastrointestinal environment [39–41].

4.3. Humans and the dynamics of acquisition

Emphasising the critical role of breastfeeding in promoting healthy infant gut microbiota, *M. smithii* was detected using real-time PCR (RT-PCR) in 27.3 % colostrum and 26.3 % milk samples [42], cultured from three colostrum and five milk samples, and a complete

genome sequence (Whole Genome Sequencing: WGS) was released for the breast milk strain C2 CSUR P5920 [42]. Accordingly, *M. smithii* was detected by PCR of the archaeal 16S rRNA gene followed by Sanger sequencing in 50/50 newborn gastric juice samples collected from day-old newborns [43]. These were further cultured in 35/50 samples in Hungate tubes containing SAB medium [44] and *Bacteroides thetaiotaomicron* (*B. thetaiotaomicron*) as the source of H₂, including 34 collected from breastfed and one from formula milk-fed neonates [43]. Further detection of *M. smithii* in meconial samples from newborns, occurring prior to any exposure to external food sources and in the absence of any evidence of contamination, has sparked a re-evaluation of conventional notions surrounding foetal microbial colonisation [45]. The correlation between C-section delivery and meconial *M. smithii* (P value = 0.004) [45] suggested the prospect of *in utero* colonisation of *M. smithii* by transferring it from the maternal gut microbiota to the placenta through the bloodstream [46], and excluded the vaginal transfer of *M. smithii*, as the physiological vaginal microbiota does not harbour *M. smithii* with the exception of cases of vaginosis [47]. Moreover, the detection of *M. smithii* in the neutral stomach juices of one- or two-day old infants adds an intriguing layer to our understanding of early microbial colonisation and suggests that *M. smithii* may be encountered even before the establishment of a diverse diet or exposure to external sources of nutrition, strongly linking it to breastfeeding, as *M. smithii* has previously been detected in maternal breast milk [42,43]. The transition from a milk-based diet to a more varied diet including complex carbohydrates, fibres and proteins is associated with significant changes in the gut microbiota [48,49]. Conversely, antibiotics prescribed in childhood can imbalance the gut microbiota [7,50]. Moreover, dietary changes, illness, and other environmental influences can also affect the abundance and activity of *M. smithii* during these formative years [51–53] (Fig. 2). Moreover, pH plays a crucial role in the acquisition of *M. smithii* and its colonisation of the human digestive tract. *M. smithii* does not survive under pH 5.6 (G. Grine, personal data). Accordingly, the immature gastric environment of newborns, marked by a neutral pH, facilitates the acquisition of *M. smithii* [43]. In contrast, the mature gastric environment, which develops acidity as early as two to three months of age, may no longer favour the presence of *M. smithii* [54]. In summary, *M. smithii* prevalence was measured during different age ranges from birth to 60–100 years, a diagram showing this variation is presented in Supplementary Fig. S2 [55]. Chi-2 test between *M. smithii* prevalence in ages 0–10 years and 60–100 years yielded a stringency significant differences between the two values (p -value: 0.0016).

5. Human microbiota

5.1. Oral microbiota

M. smithii was isolated from the oral microbiota in the background of periodontal disease samples, after the detection of methane in 20/54 samples collected from oral cavities was revealed using gas chromatography, and *M. smithii* was shown in three samples by indirect immunofluorescence and electron microscopy [56]. An investigation of 200 oral samples collected from 52 tobacco smokers and 148 non-smokers revealed the PCR detection of the 16S rRNA methanogen gene in 64/200 samples (32 %), including 47 tobacco smokers (73 %) [57]. In this series, fluorescent *in-situ* hybridization (FISH) targeting the methanogen *mcrA* gene detected 19/48 positive samples (39.58 %), including nine samples co-infected by *M. smithii* and *M. oralis* exhibiting diplococcus and bacillus morphology, respectively [57]. Culturing these 64 PCR-positive samples yielded 46 growing samples, including an oral fluid sample from one tobacco-smoker growing *M. oralis* and *M. smithii* [57]. In conclusion, this study revealed a significant correlation between tobacco smoking and the presence of *M. smithii* in the oral microbiota, suggesting that tobacco-smoking modulates the methanogen population of the oral cavity [57].




Fig. 2. Dynamics of *M. smithii* acquisition in human. *M. smithii* was transferred to newborn via different ways: *in utero* (by placenta) and after delivery (between 1 and 3 years through direct contact (kissing.), feeding style: formula milk or breastmilk. From three years and until elderly, human is exposed to several external sources that can control the presence of *M. smithii* such as diet style (meat, rice, fish.) and tobacco smoking.

5.2. Intestinal microbiota

Most knowledge about *M. smithii* in intestinal tract has derived from the study of feces, preventing an accurate localisation of *M. smithii* in the intestinal microbiota, which may depend on different conditions along different parts of the gut (the stomach, small intestine, and large intestine) such as pH, O₂ pressure, bacterial community, and mucus thickness. The acidic pH of the stomach (2 < pH < 3.5) [58], the presence of O₂ (pO₂-25 mmHg in mouse models) [59], low bacterial population [60], and a thin mucus layer make the stomach unfavourable for *M. smithii* colonisation [61]. In the small intestine, the transition from the duodenum to the ileum yields an increase in pH (from 6 to 7.5) [62], and a decrease in O₂ pressure (from 60 to 5 mmHg in mouse models) [59], which improves the growth of facultative anaerobic *Enterobacteriaceae* and *Streptococcaceae* [63] associated with *M. smithii* [64,65]. Further, the pH of the large intestine decreases from the ileum (pH = 7.5) to the caecum (pH = 6.3) [62], which does not constitute optimal conditions for *M. smithii* growth (G. Grine, personal data). In contrast, the increase once again in pH in the colon and rectum (pH = 6.5–7) [62], along with strong anaerobic conditions [59] and high mucus thickness in the colon [61] constitute ideal conditions for *M. smithii* to establish its niche and networks with members of *Bacteroidaceae* and *Ruminococcaceae* [9,66]. The prevalence of *M. smithii* in the human gut was verified by quantifying its 16S rRNA and *rpoB* gene copies in 700 faecal samples, 95.7 % of which were positive for *M. smithii*, with abundance measuring between 100 and 7.43e+10 copies of 16S rRNA, and *rpoB* copies < 1.65e+10 [6]. *M. smithii* was also detected by 16S rRNA gene sequencing in 23/33 (69.69 %) pre-term neonate meconial samples, suggesting a colonisation of this methanogenic species during pregnancy [45].

In the intestinal microbiota, *M. smithii* is one among seven methanogens, comprising of *Methanosphaera stadtmanae* (*M. stadtmanae*) [67], *Methanomassiliococcus luminyensis* [68], *Methanobrevibacter oralis* [44], *Methanobrevibacter arboriphilicus* [69], *Candidatus Methanomassilococcus intestinalis* [70] and *Candidatus Methanomethylphilus alvus* [71] which only *M. stadtmanae* [67] and *M. luminyensis* [68] having been isolated by culture, while the knowledge regarding non-*M. smithii* methanogens mostly derives from non-culture observations by molecular detection, metabarcoding and metagenomics. Studies regarding human stool methanogens yielded a prevalence of 95.7 % for *M. smithii*, 29.4 % for *M. stadtmanae* [6] and 4 % for *M. luminyensis* [55]. This high prevalence of *M. smithii* in the human gut compared to other methanogenic species is attributed to its highly efficient enzymatic machinery for converting hydrogen and carbon dioxide into methane [72], and its ability to form beneficial relationships with other gut microbes by consuming hydrogen and promoting hydrogen-sensitive bacteria [73]. Additionally, diets rich in complex carbohydrates produce more hydrogen and carbon dioxide [74], which *M. smithii* effectively utilizes, supporting its growth. *M. smithii* has unique surface proteins and glycosylation patterns that may be less recognizable by the host's immune system which help the archaeon avoid detection and attack by immune cells [72].

5.3. Lower respiratory tract microbiota

M. smithii has been detected in the lower respiratory tract microbiota by analysing sputum, bronchoalveolar lavage, and bronchial aspirates [75]. PCR and RT-PCR amplification of the archaeal and *M. smithii* 16SrRNA gene confirmed *M. smithii* in two sputum and one bronchoalveolar lavage samples [75]. In addition, morphological examination by confocal microscopy after application of FISH revealed that only one bronchoalveolar lavage sample was positive for *M. smithii*, while there were no positive results for sputum samples [75].

5.4. Milk microbiota

Using improved DNA detection protocols and microbial culture techniques associated with antioxidants, *M. smithii* was isolated from three colostrum samples and five milk samples (day 10) [42]. *M. smithii* was detected in the colostrum or milk of 5/13 (38 %) and 37/127 (29 %) mothers by culture and qPCR, respectively [42]. The distribution of maternal body mass index according to the detection of *M. smithii* suggested an association with maternal metabolic phenotype [42]. In addition, previous studies demonstrated that breast milk contains a variety of bacteria that are also found in the maternal gut, also found that the composition of the gut microbiota in mothers and their breastfed infants showed significant overlap, suggesting that the gut microbiota, including *M. smithii*, could be transferred to breast milk [76,77]. All these findings suggest that breastfeeding may contribute towards the vertical transmission of these microorganisms and may be essential to seed the infant's microbiota with these neglected critical commensals from the first hour of life.

To clarify, *M. smithii*'s activity in aerobic environments such oral cavity, blood and breast milk depends on its ability to find anaerobic niches or conditions that allow its survival and potential metabolic activity. In the oral cavity, for example, dental plaques can create microenvironments where *M. smithii* can thrive. In blood, its presence is usually indicative of an abnormal condition, suggesting that while it can be detected, it may not be actively contributing to normal physiological processes but rather involved in pathological conditions. The presence of *M. smithii* in breast milk could be transient or part of a maternal transfer of microbiota. The actual role of *M. smithii* in breast milk is still under investigation, and it remains to be seen whether it is active or simply a contaminant from the maternal gut or oral microbiota.

6. *M. smithii* in clinical microbiology

Different molecular and culture methods were performed to detect *M. smithii* in clinical samples, including RT-PCR, PCR, Sanger sequencing, and culture methods, followed by fluorescence and electron microscopy.

6.1. Microscopic detection

6.1.1. Direct microscopic examination

M. smithii vital factor 420 (F₄₂₀), producing a blue-green autofluorescence, could be detected when samples and viable cultured *M. smithii* cells were exposed to 420-nm wavelength UV light [78]. This feature was used to verify the presence and viability of *M. smithii* in culture using confocal microscopy [2,79]. As illustrated in Fig. 3C and 3D, autofluorescent *M. smithii* cells harbouring diplococcus shape with approximately size of 1.9 μm in length x 480 nm in width. The autofluorescent feature is not only produced by *M. smithii*, other methanogen species [80] and bacteria such *Clostridium* spp. [81] and *Cutibacterium* spp. [82] can emit autofluorescence. For this reason the contamination of other bacteria was minimized by using antibiotics cited below in the culture methods paragraph [83]. There is no specific staining for *M. smithii*, but Gram staining colonies demonstrates gram-positive fresh culture and gram-variable older culture *M. smithii* [2].

6.1.2. Indirect immunofluorescence

A library of rabbit antisera targeting a group of *Methanobacteriales* sp. demonstrated *M. smithii* PS and ALI strains by indirect immunofluorescence (using fluorescein isothiocyanate labelled goat immunoglobulin) [84]. This method was used to detect and characterise *M. smithii* inside faecal samples and in cultures derived from the blood of febrile patients [2,10].

6.1.3. Fluorescent in-situ hybridization

FISH is a technique used for the detection of DNA or RNA sequences inside a sample by using a fluorescent probe specific to the target sequence [85]. Accordingly, probes were designed for the specific hybridization of methanogen at large targeting the 16S rRNA gene [86] and the *mcrA* gene [57] (Table 2). The protocol, including phosphate buffered saline (PBS) washing, paraformaldehyde treatment, and 16-h incubation with probes demonstrated *M. smithii* in oral fluid, sputum, meconial and vaginal samples [45,47,57,75].




Fig. 3. *M. smithii* observed under microscope. A. Scanning electron microscopy showing *M. smithii* cell stained with PTA 10 %. B. Scanning electron microscopy showing diplococcus colonies of *M. smithii* with 500–700 nm diameter and 1.2 μm length. (TM4000 Plus tabletop, Hitachi, Tokyo, Japan) C. Three autofluorescent *M. smithii* cells exhibiting diplococcus shape with length 1.9 μm and width 480 nm approximately D. Autofluorescent *M. smithii* cells observed at 420-nm wavelength (C and D was observed with DAPI settings, 405 nm excitation, using light microscope LSM 900, Carl Zeiss Microscopy GmbH, Jena, Germany).

6.2. Molecular detection

Both preanalytical and analytical experimental steps have to be conducted to optimise the molecular detection of *M. smithii* in samples. It has been demonstrated that fresh faecal samples produced better results than older ones. One study reported that using fresh faecal samples improved the PCR detection of *M. smithii* and its correlating activity by methane detection, contrary to samples exposed to dioxygen (O₂) [87]. As for liquid stool samples, collected in cases of diarrhoea, an alternative protocol was proposed to improve DNA extraction: the application of a lyophilisation step before DNA extraction yielded 95.1 % positive samples for *M. smithii* versus 63.4 % of samples which were positive without a lyophilisation step (*P* value = 0.00043) [88]. Several PCR-based systems have been developed to amplify and detect *M. smithii* pieces of genomic DNA. Forward primer 300fEyAr and reverse primer 954rEyAr targeting the archaeal small subunit rDNA (SSU rDNA) were developed to detect *M. smithii* [89]. These two primers incorporated into PCR and applied to subgingival dental plaque DNA extracts, yielded 0.5–0.7-kb amplicons which were further purified and cloned for sequencing [89]. Of the 18 selected samples of 37/48 subgingival plaques samples which were positive for archaeal rDNA, 16/18 consisted in *Methanobrevibacter oralis* (*M. oralis*) and 2/18 consisted in *M. smithii* [89]. A few years later, new PCR assays targeting the *mcrA* of methanogens was described [90]. Faecal samples collected from healthy controls and different disease groups including Crohn's disease (CD), ulcerative colitis (UC), irritable bowel syndrome (IBS), colorectal cancer (CC) and polypectomised patients (PP) yielded 48 %, 30 %, 24 %, 48 %, 45 % and 50 % positivity in methanogens, respectively [90]. Further restriction fragment length polymorphism (RFLP) analysis of 558 *mcrA* library clones demonstrated that 510/558 (91.39 %) clones were identical to the *M. smithii* *mcrA* gene, confirming previous data on the abundancy of *M. smithii* in the gut [5,90]. Moreover, a PCR system targeting the *rpoB* gene of *M. smithii* was mentioned, resulting in 700 DNA faecal sample extracts showing the abundance of *M. smithii* in the gut, which was detected in 95.7 % of samples [6]. A DNA extraction and PCR protocol was applied to faecal sample after 0.8 µm filtration, overnight incubation with proteinase K, and DNA extraction using the NucleoSpin® Tissue Mini Kit (Macherey Nagel, Hoerd, France) [6]. A comparison of results with DNA extracted through QIAamp Stool DNA Kit (Qiagen), showed *M. smithii* 16S rRNA amplification in 50/50 (100 %) vs 44/50 (90 %) and *M. smithii* *rpoB* gene amplification in 49/50 (98 %) vs 33/50 (66 %) samples (*P* value ≤ 10⁻⁵) [6]. In addition, a semi-automated extraction protocol including glass-powder crushing and overnight digestion by proteinase K following by EZ1® extraction using the DNA Tissue Kit (Qiagen, Courtaboeuf, France) demonstrated its efficiency compared to the fully automated method [91]. Of 110 faecal DNA extracts tested by RT-PCR, 82 % were positive for the *M. smithii* 16S rRNA gene using a semi-automated DNA method for extraction, while only 32 % were positive when a fully automated DNA extraction method was applied (*P* value = 0.001) [91].

Four real-time PCR systems and two standard PCR systems targeting *M. smithii* available in the literature are shown in Table 2.

6.3. Metagenomic detection

Metagenomics explores the genetic features of microbial communities, deepening our understanding of the organisms residing in complex environmental and human samples [92]. This method entails the extraction and sequencing of microbial DNA, followed by meticulous data analysis, generating datasets in which *M. smithii* can be precisely identified and quantified [92]. Metagenomic analysis of stool samples has revealed the predominance of *M. smithii* among archaea species [93–96]. Furthermore, thanks to metagenomics, *M. smithii* has been found inside gut paleofaecal and old dental calculus samples [11,12]. In addition, *M. smithii* was detected by the metagenomics approach inside the blood cultures of febrile patients [10]. Other studies underscored the prevalence and functional contributions of *M. smithii* within the human gut microbiome, noting its widespread presence and significant impact on gut health [97]. Detailed studies have examined its gene expression patterns and protein profiles, revealing its interactions with the environment and potential effects on host metabolism [6,98]. These findings enhance our understanding of *M. smithii*'s metabolic functions and suggest its role in shaping the composition and function of gut microbiota. Moreover, mathematical models and network analyses have been

Table 2
Primers and probes used for the detection of *M. smithii* by standard PCR and qPCR [6,14,17,88,151,163].

| Target gene | PCR type | Primers and probes | Dye | Product size (bp) | References |
|---------------|----------|--|-----------|-------------------|------------|
| 16S rRNA | RT-PCR | Smit.16S-740F, 5'-CCGGGTATCTAATCCGGTTC-3' Smit.16S-862R, 5'-CTCCCAGGGTAGAGGTGAAA-3' Smit.16S FAM, 5'-CCGTCAGAAATCGTTCAGTCAG-MGB | FAM (MGB) | 123 | (88) |
| <i>rpoB</i> | RT-PCR | Ms <i>rpoB</i> F, 5'-AAGGGATTTGCACCCAACAC-3' Ms <i>rpoB</i> R, 5'-GACCACAGTTAGCACCCCTTGG-3' Ms <i>rpoB</i> VIC, 5'-ATTTGGTAAGATTTGTCCGAATG-3' | VIC (MGB) | 70 | (6) |
| Repeat region | RT-PCR | <i>M. smithii</i> -F, 5'-ACCATAACyATCAGCAGCATTAT-3' <i>M. smithii</i> -R, 5'-AGTATTGGTGAAGGATTTACTGT-3' <i>M. smithii</i> probe, 5'-ACCyTTATCAGCTTTACCATTAATyAAAG-3' | FAM (MGB) | N/A | (151) |
| <i>mcrA</i> | PCR | MM_Mbs_Fw 5'-gCACCTAACAAACACggACA-3' MM_Mbs_Rv 5'-TTTggTCCTCTCATTTCgAg-3' | – | 446 | (163) |
| <i>nifH</i> | PCR | Mnif-342f 5'-AACAGAAAACCCAGTGAAGAG-3' Mnif-363r 5'-ACGTAAAGGCACTGAAAAACC-3' | – | 222 | (14) |
| <i>nifH</i> | RT-PCR | Mnif 202F, 5'-GAAAGCGGAGGTCTCGAA-3' Mnif 353R, 5'-ACTGAAAAACCTCCGCAAAC-3' Mnif Probe, 5'-CGGACGTGGTGAACAGTAGCTA-3' | FAM (MGB) | N/A | (17) |

used to investigate its energy conservation mechanisms and interactions within microbial communities, which are essential for predicting how *M. smithii* responds to environmental changes, such as dietary shifts and alterations in microbial community dynamics [99, 100]. Additionally, bioinformatics approaches utilizing metagenomic data have predicted its functional capabilities and implications for maintaining gut homeostasis [94,101]. These analyses highlight the complex relationships between *M. smithii* and other microbes, offering insights into its potential role in influencing gut health and metabolic disorders. Furthermore, systems biology approaches have been employed to quantify metabolic changes induced by diet, demonstrating how *M. smithii* adapts to dietary variations and its possible contributions to metabolic disorders [102]. This comprehensive perspective emphasizes the diverse roles of *M. smithii* in the gut ecosystem, from methane production to metabolic regulation, making it a key subject of research in microbiology and human health.

6.4. Isolation by culture

Despite several effective protocols being reported for the isolation and culture of *M. smithii*, only four strains (PS DSM 861; F1 DSM 2374; ALI DSM 2375, and B181 DSM 11975) are available in the German collection of microorganisms and cell cultures GmbH (DSMZ) (<https://www.dsmz.de>). The type strain PS is also available from the Japan Collection of Microorganisms (JCM) (<https://jcm.brc.riken.jp>) (Table 3). In addition, 15 isolates are available from the Collection de Souches de l'Unité des Rickettsies (CSUR) WDCM 875 (Table 3). *M. smithii* was initially isolated by culture by incubating faecal samples anaerobically in an H₂-CO₂ (80:20) atmosphere and 2-atm pressure after enrichment in the same conditions with agitation [2]. In these conditions, methane (CH₄) production could be monitored after seven-day incubation by gas chromatography (GC) as a proxy for *M. smithii* growth [2,44,47,103,104]. Serial dilutions of methane production-positive samples were then incubated in Balch medium 1 with 2 % Difco agar under a 1-atm H₂-CO₂ atmosphere, and colonies resulting from the most diluted culture were sub-cultured on agar Balch medium under anaerobic conditions to obtain pure cultures [2]. SAB medium was then proposed as a versatile medium to broaden isolation by culture of stool methanogens, sparing 1–3 days for *M. smithii* growth compared to DSMZ medium which is more specific for methanogens [44]. Moreover, specimens which were negative for *M. smithii* by PCR grew after three weeks of incubation in the SAB medium, whereas no growth was detected in the DSMZ medium [44]. Further co-incubation of faecal samples with H₂-producing *B. thetaiotaomicron* led to unprecedented aerobic culture of *M. smithii* [105]. In detail, the culture system consisted of one upper chamber containing a Petri dish with solid SAB medium inoculated with *M. smithii* and *B. thetaiotaomicron* co-culture and a lower chamber containing SAB broth inoculated with *B. thetaiotaomicron* [105]. Nine days of incubation at 37 °C yielded methane-producing colonies identified by quantitative real-time PCR (RT-PCR) targeting the *M. smithii* 16S rRNA gene [105]. Finally, a patented GG culture medium was designed for *M. smithii* isolation by adding formate and acetate without a source of H₂ or carbon dioxide (CO₂), maintaining the viability of *M. smithii* in samples transported at ambient atmosphere and temperature for 15 days, and greatly facilitating routine isolation and evading the use of exploding H₂ gas [83]. In summary, three culture media were available in literature: DSMZ medium, SAB medium and GG medium. These media share 27 components, while 17 components are common between the GG medium and the SAB medium, one component (sodium resazurin) is common between the SAB medium and the DSMZ medium, and there are no mutual components between the GG and DSMZ media (Venn diagram; Fig. 4). Moreover, the GG medium is the only one to contain glutathione, uric acid and ascorbic acid. In contrast, the DSMZ medium is the only one to contain hydrochloric acid (25 %), while no specific components were present in the

Table 3
Summary of *M. smithii* strains available in microbial collection databases [1,2,24,164].

| Collection name | Strain designation | Isolation source | Storage conditions | reference |
|-----------------|------------------------|------------------------------|---------------------|-----------|
| DSMZ/JCM | PS; DSM 861; JCM 30028 | primary sewage digester, USA | Liquid medium | (1) |
| DSMZ | F1; DSM 2374 | Human feces, USA | Liquid medium | (2) |
| DSMZ | ALI; DSM 2375 | Human large intestine, USA | Liquid medium | (164) |
| DSMZ | B181; DSM 11975 | Human feces, USA | Liquid medium | (24) |
| CSUR | Q5487 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5502 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5505 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5701 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5704 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5705 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5707 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5708 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5709 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5711 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5713 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5714 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5715 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5716 | Human feces, France | Lyophilised; -80 °C | |
| CSUR | Q5718 | Human feces, France | Lyophilised; -80 °C | |

*DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures) <https://www.dsmz.de/>.

*JCM: Japan collection of microorganisms <https://jcm.brc.riken.jp>.

*CSUR: Collection de Souches de l'Unité des Rickettsies <https://csur.eu/>.

SAB medium. All media were used in anaerobic conditions with N_2/CO_2 gases, while H_2 was only added to the SAB and DSMZ media (Fig. 4). As for identification of colonies, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) identified 28 cultured environmental species belonging to 12 Archaea families with reliable results [106]. Improvements in the protocol were made by adding a mechanical step for lysing methanogen cells which enlarged the spectrum of archaeal species tested, including human-associated archaea and *M. smithii* [107]. Interestingly, three *M. smithii* human gut isolates exhibited an identical spectral profile which differed from that derived from a sewage digester strain ATCC 35061, showing one additional 6050-Da peak (quality score 7). This illustrated the phenotypic diversity of *M. smithii* [107]. A further study, using a database based on the MS profiles of 16 methanogens, identified 21 human feces *M. smithii* isolates and clustered them within six *M. smithii* genotypes [108]. MALDI-TOF-MS was used to identify faecal *M. smithii* genotypes cultured anaerobically with *Bacteroides thetaiotaomicron* [109]. Taken as a whole, these studies demonstrate the practicability and usefulness of MALDI-TOF-MS for the rapid identification of *M. smithii* colonies, applicable for research and clinical microbiology. The culture, molecular, microscopic and metagenomic methods applied to detect *M. smithii* in clinical samples are shown in Fig. 5.

7. Microbiology of *M. smithii* cell variants

We recently discovered *Candidatus Nanopusillus phoceensis* associated with *M. smithii* in the human digestive tract microbiota after PCR detection of *M. smithii* in 87/110 (79 %) faecal samples and the co-detection of *M. smithii* and Nanoarchaeota in 17/87 (20 %) faecal samples [110]. In light of the similarity with data we reported on another nanoarchaeon named *Nanopusillus massiliense*, observed by electron microscopy to be tightly associated with *Methanobrevibacter oralis* (*M. oralis*), we inferred that the same situation may exist for *M. smithii/Ca. N. phoceensis*. We therefore determined two *M. smithii* cellular forms that we named *M. smithii* small cell variant (SCV) (with no association with *Ca. N. phoceensis*), and *M. smithii* large cell variant (LCV) (*M. smithii* associated with *Ca. N. phoceensis*) [110,111].

7.1. Genomic diversity

M. smithii genome comprises one chromosome (no plasmid detected to date), the genomic characteristics of which (genome length, number of coding sequences (CDS), number of CRISPR, coding ratio, and GC%) are displayed in Table 1 for 95 *M. smithii* genome sequences available at the time of this review. No obvious difference between the different strains with the respect of source, human and pig *M. smithii* genomes yielded approximately same genome size measuring in average 1.6–1.7 Mb with 31 % GC content and 83–85 % coding ratio. The characteristics of four *M. smithii* complete genomes (ATCC 35061, KB11, CE91-St67, CE91-St68), including GC%, GC skew, as well as their restriction maps, are shown in Fig. 6. As an example, *M. smithii* ATCC35061 type strain derived from a primary sewage digester has a 31 % GC content, a 1 853 160 base pair (bp) genome sequence with a 90.2 % coding ratio of 1795 coding genes, 34 tRNAs, two rRNA clusters, and two CRISPR arrays [72] (Table 1). Interestingly, the genomic sequences of digestive tract isolates exhibit a higher number of genes coding for cell wall structure, defence, and metabolism of bacteria-end products than environmental *M. smithii* strains (binomial test; $P < .01$). Nevertheless, the genome sequences of the human feces *M. smithii* strain KB11




Fig. 4. Venn diagram comparing three culture media of *M. smithii* (DSMZ, SAB, and GG media). These media share between them 27 components including N_2/CO_2 . SAB and GG media have 17 common components, SAB et DSMZ have sodium resazurin and H_2 gas as common components and no shared components between GG and DSMZ media. Specific components were present in GG medium (Glutathion, uric acid, and ascorbic acid) and DSMZ medium (Hydrochloric acid).




Fig. 5. *M. smithii* detection methods from clinical samples. Four protocols were shown for *M. smithii* investigation: a. Culture methods followed by methane measurement by GC, MADI –TOF identification or WGS b. Microscopy methods by autofluorescence, FISH observations or electron microscopy c. Molecular detection by qPCR and PCR followed by sequencing d. Metagenomic screening of clinical samples.




Fig. 6. Illustration showing genomic diversity between four complete genomes of *M. smithii* (ATCC 35061, CE91-St67, CE91-St68 and KB11). A. GC % (black graph) and GC skew (Green and purple graphs) (C-G/C + G), GC skew negative represents more G bases than C bases in the position, GC skew positive represents more C bases than G bases in the position. B. Restriction maps relative to *M. smithii* genomes using 678 restriction enzymes, 18 enzymes do not cut inside these four genomes while *SrfI* does not cut KB11 (Supplementary information, Table 1). Figures obtained using Proksee (<https://proksee.ca>) and SnapGene (<https://snapgene.com>) programs.

(CP017803.1) is 47 615-bp shorter than that of *M. smithii* ATCC35061 (CP000678.1). A C-terminal deletion includes DNA helicase UvrD (Msm_0731) and gaps in the adhesin-like protein (BK798_03360), while an additional 23 180-bp region (500216–523396) encodes for hypothetical proteins, type I restriction-modification system, and transposases [72,112]. *M. smithii* genomic diversity was also assessed by multispacer sequence typing (MST) through developing PCR systems targeting four intergenic spacers in reference *M. smithii* ATCC35061 [113]. Applying these systems to four *M. smithii* genome sequences and 22 *M. smithii* digestive tract isolates yielded 15 different genotypes: three distinct genotypes corresponding to each of the F1, AL1, and B181 reference genomes; five genotypes for five oral isolates and nine genotypes for seven gut isolates with two genotypes shared between the oral cavity and gut isolates [113]. Finally, comparing clusters of 29 gene ontologies in intestinal *M. smithii* and *Methanospaera stadmanae* (genome size: 1 767 403 bp) indicated that *M. smithii* presented more groups relative to the surface variation (48 vs 30), persistence (8 vs 4) and metabolic activity (480 vs 389) [72]. In *M. smithii* LCVs, our further genome analysis of *Ca. N. phoceensis* identified a SAM-dependent methyltransferase (QFW68505.1) and glycosyltransferase (QFW68504.1) most probably transferred as a whole from Nanoarchaeota virus NAV1 to *M. smithii* LCVs (I. MALAT, personal data), suggesting that LCVs may have an unique glucoside-decorated cell wall profoundly modifying LCV cell wall properties such as recognisability by residing immune cells such as dendritic cells, macrophages,

plasma cells in the mucosae and Peyer patches in the gut-associated lymphoid tissues (Fig. 7).

7.2. Structural morphology and cell wall composition

M. smithii SCVs look like 1.5–2 μm coccobacilli (electron microscopy) which are blue-green autofluorescent due to F_{420} -reducing hydrogenase, a cofactor implicated in hydrogen metabolism and methane secretion with a 420-nm emission peak (Fig. 3). *M. smithii* is not motile, exhibiting a gram-positive cell wall lacking bacterial peptidoglycan, instead being composed of pseudomurein proteins forming a mesh-like structure surrounding the cell and providing strength and rigidity [1,114,115]. Specific sugar units and glycosidic linkages differ between pseudomurein and peptidoglycan, with pseudomurein consisting of N-acetylglucosamine (NAG) and N-acetylglucosaminuronic acid (NAT) repeats connected by β -1,3-glycosidic bonds, differing from N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) which are connected by β -1,4-glycosidic bonds in bacterial peptidoglycan [114,116,117]. The pseudomurein cell wall serves as a protective layer, conferring resistance to *M. smithii* against lysozyme and a wide range of peptidoglycan-targeting antibiotics in addition to osmotic pressure and mechanical stress, and also helps to maintain cell shape, preventing cell collapse and providing overall cell stability [118] (Fig. 8). Internal to the cell wall, the cell membrane is composed of a lipid monolayer constituted by isoprenoid chains rather than the lipid bilayer constituted by unbranched fatty acids observed in bacterial and eukaryotic membranes [119,120]. These isoprenoid chains are linked to glycerol by ether bonds, yielding an hydrophobic core barrier regulating ions and molecule flux, maintaining cellular homeostasis and providing stability and adaptability of *M. smithii* in the anaerobic environment [121] (Fig. 8). Screening Nanoarchaeota in human stool samples using PCR targeting the 30S L12 gene yielded 17 positive results, which were also positive for *M. smithii* [110]. Analysing the 17 positive samples by FISH co-localised *M. smithii* and *Ca. N. phoceensis* and further electron microscopy observation demonstrated *M. smithii* LCVs enlarging *M. smithii* with one 100–400 nm coccobacilli [110].

7.3. Physiology

M. smithii is a strictly aero-intolerant archaeon and experimental deadly exposure to ambient air varied from 15 to 30 min [10], a timescale which could guide the sampling, transport and storage of specimens in the search for *M. smithii* by culture. Accordingly, *M. smithii* plays a critical role in the metabolic dynamics of anaerobic ecosystems such as mammals, including the human digestive tract via hydrogenotrophic methanogenesis, including the reduction of CO_2 by H_2 into gaseous methane following this reaction: $4\text{H}_2 + \text{CO}_2 \rightarrow \text{CH}_4 + 2\text{H}_2\text{O}$ [72]. *M. smithii* possesses a repertoire of enzymes crucial for its distinctive metabolic pathways.




Fig. 7. Schematic illustration of *M. smithii* and *M. smithii*-Nanoarchaeota translocating and residing scenario from gut to blood. *M. smithii* alone can cross intestinal immune barrier and cells arriving to the blood. In contrast, *M. smithii*-Nanoarchaeota constitutes a novel microorganism with different cell size and different membrane profile (i.e., glycosylation caused by transferred glycosyltransferase gene from NAV1 to Nanoarchaeota) which inhibits intestinal barrier crossing. Scheme drawing using BioRender (<https://www.biorender.com/>).




Fig. 8. Schematic illustration comparing *M. smithii* cell wall with bacterial cell membrane. *M. smithii* cell wall is composed of NAG and NAT connected by β -1,3-glycosidic bonds while bacterial cell wall is composed of NAM and NAG connected by β -1,4-glycosidic bonds. *M. smithii* cell membrane is constituted of glycerol with branched isoprene chain forming monolayer structure, while bacterial membrane is constituted of glycerol with unbranched fatty acids forming bilayer structure.

Methyl-Coenzyme M Reductase (MCR) is central in methanogenesis, catalysing the final step of methane synthesis by converting methyl-coenzyme M and coenzyme B to methane and coenzyme M [72]. In addition, the formylmethanofuran pathway relies on the activity of formylmethanofuran dehydrogenase (Fwd) for the reduction of CO_2 to formylmethanofuran, a pivotal intermediate in methanogenesis [72]. Furthermore, hydrogenases, including F_{420} -reducing hydrogenase, enable the hydrogenotrophic methanogenic capabilities of *M. smithii* [72]. All these methanogenesis reactions were illustrated in Fig. 9. The intricate interplay between these enzymes underscores the metabolic adaptability of *M. smithii* within the complex ecosystem of the gut microbiome.

7.4. Antiseptic and antibiotic susceptibility

The pattern of *M. smithii* antibiotic susceptibility was evaluated on 16 *M. smithii* isolates from freshly collected feces including the *M. smithii* ATCC35061 type strain [122]. All tested isolates exhibited high resistance to penicillin G, cephalothin, vancomycin, streptomycin, gentamicin, ciprofloxacin, and clindamycin (minimal inhibitory concentration (MIC) > 64 mg/L) [122]. In contrast, 10/15 isolates were susceptible (MIC < 16 mg/L) to metronidazole, one was intermediately susceptible (MIC = 16 mg/L), and five were resistant (MIC > 16 mg/L) [122]. Further studies highlighted resistance to chloramphenicol (MIC \leq 25 mg/L) and susceptibility to bacitracin (MIC \leq 4 mg/L), metronidazole, ornidazole, and fusidic acid [123,124]. Furthermore, *M. smithii* growth inhibition was observed after incubation with antimicrobial peptides (AMPs) human cathelicidin LL32 (MIC = 1 μM), porcine NK-lysin (NK2) derivatives (MIC = 3 μM), and synthetic antilipopolysaccharide Lpep 19-2.5 (MIC = 3 μM) while human cathelicidin LL20 and porcine




Fig. 9. *M. smithii* methanogenesis pathways from formate and H_2/CO_2 . H_2 , dihydrogen; CO_2 , Carbone dioxide; CH_4 , methane; FdhAB, formate dehydrogenase subunits; Fwd, formylmethanofuran dehydrogenase; MCR, methyl-coenzyme M reductase; CoB, coenzyme B; CoM, coenzyme M; MFN, methanofuran; CoM, coenzyme M.

NK-lysin C7S had MIC >10 μM [51]. In addition, transferring the *sat* gene to study methanogen resistance to nourseothricin led to using this gene as a selection marker for methanogens [125]. Among the species tested, *M. smithii* exhibited high susceptibility to nourseothricin, but colonies were still observed after one month of incubation with nourseothricin. WGS revealed four mutants in three hypothetical genes and a potassium transporter TrkA [125]. Lovastatin was also evaluated *in vitro* and no CH_4 was detected after five days of incubation of *M. smithii* with 4 $\mu\text{g/mL}$ lovastatin compared to the control [126]. PCR amplifications indicated an increased expression of HMG genes due to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-Co-A) reductase (HMGR) inhibition by lovastatin leading to the inhibition of cell membrane synthesis [126]. No data issued regarding the susceptibility of *M. smithii* to decontaminants and antiseptics, except for squalamine exhibiting a MIC ≤ 1 mg/L [127].

8. *M. smithii* microbial interplays and networks

M. smithii was revealed to have relationships with bacteria, fungus and viruses, as well as with its host, constituting a wide network and shedding light on the importance of thoroughly characterising such interactions (Fig. 10).

8.1. Bacteria

The interactions between *M. smithii* and bacteria in the human gut is an intriguing aspect of the complex microbial ecosystem within the digestive system. Various gut bacteria, including genera like *Bacteroides*, *Prevotella*, *Ruminococcus* and *Faecalibacterium*, participate in the physiology of *M. smithii* through the production of hydrogen gas (H_2), an essential compound of methanogenesis [38, 66]. The metabolism of H_2 in the *in vitro* model designed to scrutinise the mutual interaction between *M. smithii* and *Anaerostipes rhamnosivorans* demonstrated a notable exchange of formate and hydrogen from the bacterium to methanogen [128]. This exchange coincided with a substantial increase in levels of bacterial butyrate production [128]. Moreover, examination of the interplays between *M. smithii* and *B. thetaiotaomicron*, a pivotal constituent of the gut microbiota, revealed a fascinating dynamic. The fermentation products and hydrogen produced by *B. thetaiotaomicron* served as vital sustenance for the thriving growth of *M. smithii* [73]. Paradoxically, the accrual of these fermentation byproducts triggers a disruption in the metabolic secretion pattern of *B. thetaiotaomicron*, ultimately impeding the growth of *M. smithii* [73]. Furthermore, the H_2 produced by *Christensenella minuta* enhances and supports the metabolic activities of *M. smithii* more efficiently than the presence of *Bacteroides thetaiotaomicron* [129]. Furthermore, to enhance our




Fig. 10. Illustration showing *M. smithii* and its microbial networks. Four groups of microorganisms showed interactions with *M. smithii* including bacteria, fungi, nanoarchaeota and viruses. Figure drawing using Cytoscape (<https://cytoscape.org/>).

understanding of the role of *M. smithii* in the human gut microbiota and its interactions with other microbial families, an *in vitro* culture model was employed using *M. smithii* PCR-positive stool samples, initially devoid of methane post batch culture [130]. Intriguingly, the experiment revealed a depletion in *Desulfovibrionaceae* 200 h after *M. smithii* inoculation [130]. Conversely, inhibiting *M. smithii* using 2-bromoethanesulfonic acid resulted in an elevation in the *Desulfovibrionaceae* population ($r_s = -0.841$, P value < 0.05) [130]. These findings underscore the inhibitory impact of *M. smithii* on sulfate-reducing bacteria, suggesting a competitive relationship, particularly in terms of H_2 utilisation.

8.2. Viruses

The human virome encompasses a vast and diverse collection of viruses that inhabit human niches, influencing health, disease, and interactions with other microbial communities [131]. In the human digestive tract, the main families are found to belong to tailed double stranded DNA bacteriophages referred to as *Caudoviricetes* sp [132]. Recently, bioinformatic analyses have revealed a vast number of intestinal *Caudoviricetes* sp. nucleic sequences inserted in genomes of *M. smithii* derived from the human gut, suggesting infection of *M. smithii* by these bacteriophages [133–135].

8.3. Fungi

To date, no studies are available about *M. smithii*-fungi interactions inside humans. In contrast, the interaction between *M. smithii* and ruminal fungi has been better clarified. *M. smithii* co-culture with rumen anaerobic fungi *Neocallimastix frontalis* (*N. frontalis*) and *Piromonas communis* (*P. communis*) led to a decrease in fungal susceptibility to the ionophore antibiotics monensin and lasalocid, while in contrast no protective role of *M. smithii* was shown after its incubation with fungi in the presence of coumarin or p-coumaric acid [136,137]. Moreover, co-culture of *M. smithii* with *N. frontalis*, *P. communis* and *Sphaeromonas communis*, another anaerobic rumen fungus, increases their metabolic enzyme activity, thus xylan and cellulose fermentation, leading to the release of more acetate, xylose and hexose [138,139]. In addition, ryegrass and lignified secondary wall degradation was improved when *N. frontalis*, *Piromyces* and *Caecomyces* co-cultured with *M. smithii* [140]. In contrast, *Aspergillus terreus* in fermented rice straw extracts inhibits the growth of *M. smithii* and resulting methane production [141]. In greater depth, lovastatin secreted by fungus is able to inhibit 3-hydroxy-3methyl glutaryl CoA reductase, a crucial enzyme involved in the synthesis of the methanogenic cell membrane [141].

8.4. Host

In humans, the release of proinflammatory cytokines TNF- α and IL-1 β was investigated using peripheral blood mononuclear cells (PBMC) and monocyte-derived dendritic cells (moDCs) collected from in healthy donors exposed to *M. stadtmanae*, *M. smithii* and *M. luminyensis* [142]. In addition, Bang et al. found that *M. stadtmanae* and *M. smithii* interfered with moDC expression of antimicrobial peptide genes [142]. The same experiments conducted with the Caco-2/BBe intestinal epithelial cells did not result in cytokine induction, suggesting that the recognition of *M. smithii* and *M. stadtmanae* might be restricted to immune cells [142]. Furthermore, in mice, the inhalation of *M. smithii* induced a tenfold accumulation of myeloid DCs compared to saline inhalation [143]. The term “archaeosome” was coined for spontaneous or synthetic liposomes composed of archaeal lipids and it has been showed that bovine serum albumin immunisation was more effective when *M. smithii*-derived archaeosomes were employed, as compared with conventional liposomes [144,145].

9. *M. smithii* in pathology

M. smithii, the predominant methanogen in the human gut, is found in higher concentrations in individuals with conditions such as constipation-predominant IBS, small intestinal bacterial overgrowth, and obesity [146,147]. Its production of methane is believed to slow intestinal transit time, exacerbating symptoms of constipation and contributing to bloating and discomfort [146]. Additionally, its presence has been linked to increased efficiency in extracting calories from food, which may play a role in weight gain and obesity [72,148]. Thus, *M. smithii* is implicated in both the manifestation and progression of these pathologies, highlighting its potential as a therapeutic target for related disorders.

9.1. Dysbiosis

9.1.1. Urinary tract infections

M. smithii was detected in 9 % of urine samples collected from patients with urinary infections. In addition, 53 %, 18 %, and 3 % of *M. smithii* in infected urine samples were associated with *Escherichia coli*, *Klebsiella pneumoniae* and *Enterobacter* sp., respectively [64].

9.1.2. Bacterial vaginosis

Methanogenic activity was detected in anaerobic vaginal fluid samples collected from patients with bacterial vaginosis (BV). After enrichment steps, methane monitoring by GC and indirect immunofluorescence assay, two isolates of *M. smithii* were identified close to strains *M. smithii* PS and *M. smithii* ALI [104]. Further study investigated *M. smithii* in bacterial vaginosis [47]. A group of 33 vaginal samples collected from BV patients showed 32 of them were positive by 16S rRNA RT-PCR for *M. smithii* [47]. Moreover, nine *M. smithii* strains were isolated in anaerobic SAB medium and two bacterial vaginosis samples showed the presence of *M. smithii* by FISH after

microscopic examination [47]. A patent on *M. smithii* as a biomarker for bacterial vaginosis has been deposited (WO 2019/122545 A1) [149].

9.1.3. Severe acute malnutrition

M. smithii has been defined as a roughly missed microorganism in the guts of African children with severe acute malnutrition due to disruptions in diet and lack of quality in consumed nutrients [150]. Moreover, a severe irreversible depletion in *M. smithii* was demonstrated by PCR screening of faecal samples from SAM children compared to controls, leading to the detection of *M. smithii* only in 4.2 % of cases compared to 40.9 % of controls [7]. Therefore, the role of *M. smithii* in malnutrition is linked to its involvement in the gut microbiome's energy-harvesting capabilities. Studies have shown that *M. smithii* is more abundant in the gut microbiota of obese individuals, suggesting it may contribute to more efficient caloric extraction from food, potentially exacerbating conditions related to overnutrition. Conversely, its role in malnutrition could be investigated in the context of its interactions with other gut microbes and its impact on nutrient absorption.

9.2. Abscesses

9.2.1. Muscular abscesses

M. smithii was isolated from a paravertebral muscular abscess sample collected from a 41-year-old patient [9]. Molecular detection of archaeal 16S rRNA and *mcrA* genes relative to *M. smithii* was verified by sequencing and *in vitro* resistance of the *M. smithii* isolate to amoxicillin-clavulanate and susceptibility to metronidazole was revealed after incubation of the strain with SAB medium supplemented with these antibiotics followed by methane production measurement using GC [9].

9.2.2. Cerebral abscesses

Only one study detected *M. smithii* from a brain abscess sample [151]. Of 18 brain abscess specimens, only one revealed *M. smithii* by RT-PCR [151].

9.2.3. Dental abscesses

M. smithii was detected and cultured from subgingival dental plaque samples [152]. After anaerobic incubation of collected samples in SAB medium, DNA extraction, followed by PCR targeting the *mcrA* gene of methanogens and sequencing, revealed the presence of *M. smithii* in 2/65 (3 %) of samples derived from moderate risk group patients. *M. smithii* was isolated in one sample after four months of anaerobic incubation at 37 °C [152].

9.2.4. Chronic rhinosinusitis

Methanogens were searched in 116 sinus surgical specimens collected surgically from patients diagnosed with refractory sinusitis [153]. Molecular detection by PCR yielded 12 methanogen-positive samples related to nine patients (10.3 %) [153]. Interestingly, *M. smithii* was identified in four patients after further analysis of methanogen positive samples by FISH and amplicon sequencing [153].




Fig. 11. *M. smithii* repertoire in human flora and pathologies. *M. smithii* was detected along the gastrointestinal tract including oral cavity, newborn stomach, and gut. Also in lower respiratory tract and breast feeding milk. In pathologies, *M. smithii* was detected in abscesses (muscle abscess, cerebral abscess, and dental abscess), dysbiosis (urinary infection and vaginosis) and febrile patients with bacteremia, noting its increase in feces of colorectal cancer patients and its absence in severe acute malnutrition patients. Scheme drawing using BioRender (<https://www.biorender.com/>).

9.3. *Archaemia and endocarditis*

M. smithii was detected and isolated from the blood of febrile patients, specifically those with infective endocarditis [10]. In detail, 27/5594 (0.5 %) anaerobic blood cultures collected from patients with fever showed the presence of bacterial species and were PCR-positive for *M. smithii* [10]. Further investigations were then applied to three samples relative to infectious endocarditis patients: *M. smithii* associated with *S. aureus* was detected by autofluorescence and electron microscopy in one blood culture, and two *M. smithii* strains, BC55 and BC84, associated with *S. mutans* and *S. epidermidis*, respectively, were isolated and sequenced from two blood culture of endocarditis patients [10]. A summary of the repertoire of *M. smithii* in human flora and pathological cases is shown in Fig. 11.

9.4. Others

9.4.1. Colon cancer

To investigate the archaeome in the human gut concerning colorectal cancer (CRC), a comprehensive analysis was conducted on 390 faecal metagenomic datasets, encompassing both apparently healthy individuals (n = 198) and CRC patients (n = 192) [154]. The data were sourced from diverse geographical regions, including Europe (Austria, Germany, and Italy) and Asia (Japan, China, and India), providing a broad perspective on archaeal species composition [154]. Within the pool of 217 identified archaeal species, the median density of *M. smithii* per faecal sample was significantly higher in samples collected from patients diagnosed with CRC than in apparently healthy individuals (Kraken abundance; mean: 36740,9844 VS 7693,05051) (P value < 0.001) [154], consistent with findings in an independent study that specifically emphasised Indian CRC cases [155]. Conversely, an investigation involving 73 Chinese CRC patients, using the MaAsLin approach (multivariate associate with linear models) ($Q < 0.1$), revealed an increase in the density of halophilic archaea and a decrease in methanogenic archaea, including *M. smithii*, compared to a cohort of 92 apparently healthy individuals [156]. Taken as a whole, these well-designed studies reported apparently contradictory results, suggesting that the faecal microbiota is not appropriate to resolving the question of the relationship between *M. smithii* and CRC. Further studies of cancerous tissues compared to apparently healthy tissue collected from paired individuals (including auto-controls) is required.

10. Conclusions and perspectives

M. smithii stands as an intricate and overlooked player in the microbiota physiology and associated pathologies. The culmination of several pieces of research has revealed the unique attributes of this methanogenic archaeon, painting a picture of its diverse roles and interactions within the complex ecosystems of the human body [157–159]. The taxonomic distinctiveness of *M. smithii*, confirmed through meticulous phenotypic, genetic, and genomic analyses, underscores its significance [160,161]. Its ability to detoxify hydrogen from bacterial fermentations and converting it into methane, positions *M. smithii* as a key contributor to metabolism-driven microbial networks [162]. The symbiotic association with *Ca. Nanopusillus phoceensis* [110] adds an additional layer of complexity, giving rise to distinct cell variants and influencing the dynamics of microbial communities. The model organism status of *M. smithii* in pathogenicity by association is a paradigm-shifting revelation. Its translocation with bacteria, the induction of detectable inflammatory responses, and co-culture from various bodily fluids open perspectives for exploring not only its physiological impact but also its potential implication in diseases. However, the limited availability of *M. smithii* strains in microbial collection databases represents a critical gap in our understanding. Only four strains are currently documented, prompting a call for a comprehensive effort to expand this repository. The need for in-depth investigations into the *in utero* acquisition, lifespan dynamics, diversity, and susceptibility of *M. smithii* is increasingly evident, holding promise for breakthroughs in microbiota-related studies.

Efforts should concentrate on expanding microbial collections to encompass a broader spectrum of *M. smithii* strains from various sources, including animals and derived products, facilitating a more nuanced exploration of its genotypic and phenotypic diversity. In parallel, investigations into the *in utero* acquisition of *M. smithii* could unravel critical aspects of early microbial colonisation and its potential implications for later health outcomes. Longitudinal studies tracking *M. smithii* throughout an individual's life will provide insights into its dynamic role within the microbiota, shedding light on its resilience and adaptability. Furthermore, advances in metagenomics, metatranscriptomics, metaproteomics, and metabolomics will enable a systems-level understanding of the host-microbe dialogue, offering unprecedented insights into the functional dynamics of these microbial communities.

The limited research works about *M. smithii* emphasize the importance of raising awareness about its roles and potential significance in health and diseases. Educational programmes and interdisciplinary collaborations could foster a collective effort to propel *M. smithii* into the forefront of microbiota research.

CRedit authorship contribution statement

Ihab Malat: Writing – original draft, Methodology, Conceptualization. **Michel Drancourt:** Writing – original draft, Visualization, Methodology, Formal analysis, Conceptualization. **Ghiles Grine:** Writing – original draft, Validation, Supervision, Methodology, Formal analysis, Data curation, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.heliyon.2024.e36742>.

References

- [1] W.E. Balch, G.E. Fox, L.J. Magrum, C.R. Woese, R.S. Wolfe, Methanogens: reevaluation of a unique biological group, *Microbiol. Rev.* 43 (1979) 260–296, <https://doi.org/10.1128/mr.43.2.260-296.1979>.
- [2] T.L. Miller, M.J. Wolin, E. Conway de Macario, A.J. Macario, Isolation of Methanobrevibacter smithii from human feces, *Appl. Environ. Microbiol.* 43 (1982) 227–232, <https://doi.org/10.1128/aem.43.1.227-232.1982>.
- [3] C. Dh, Respiratory hydrogen and methane as affected by consumption of gas-forming foods, *Gastroenterology* 51 (1966). <https://pubmed.ncbi.nlm.nih.gov/5945818/>. (Accessed 15 January 2022).
- [4] P.M. Nottingham, R.E. Hungate, Isolation of methanogenic bacteria from feces of man, *J. Bacteriol.* 96 (1968) 2178–2179.
- [5] T.L. Miller, M.J. Wolin, Enumeration of Methanobrevibacter smithii in human feces, *Arch. Microbiol.* 131 (1982) 14–18, <https://doi.org/10.1007/BF00451492>.
- [6] B. Dridi, M. Henry, A. El Khéchine, D. Raoult, M. Drancourt, High prevalence of methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol, *PLoS One* 4 (2009) e7063, <https://doi.org/10.1371/journal.pone.0007063>.
- [7] A. Camara, S. Konate, M. Tidjani Alou, A. Kodio, A.H. Togo, S. Cortaredona, B. Henrissat, M.A. Thera, O.K. Doumbo, D. Raoult, M. Million, Clinical evidence of the role of Methanobrevibacter smithii in severe acute malnutrition, *Sci. Rep.* 11 (2021) 5426, <https://doi.org/10.1038/s41598-021-84641-8>.
- [8] S.B. Ghavami, E. Rostami, A.A. Sephay, S. Shahrokh, H. Balaii, H.A. Aghdaei, M.R. Zali, Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases, *Microb. Pathog.* 117 (2018) 285–289, <https://doi.org/10.1016/j.micpath.2018.01.029>.
- [9] V.D. Nkamga, R. Lotte, P.-M. Roger, M. Drancourt, R. Ruimy, Methanobrevibacter smithii and Bacteroides thetaiotaomicron cultivated from a chronic paravertebral muscle abscess, *Clin. Microbiol. Infect.* 22 (2016) 1008–1009, <https://doi.org/10.1016/j.cmi.2016.09.007>.
- [10] M. Drancourt, K. Djemai, F. Gouriet, G. Grine, A. Loukil, M. Bedotto, A. Levasseur, H. Lepidi, J. Bou-Khalil, S. Khelaifia, D. Raoult, Methanobrevibacter smithii aetiology in febrile patients with bacteraemia, including those with endocarditis, *Clin. Infect. Dis.* 73 (2021) e2571–e2579, <https://doi.org/10.1093/cid/ciaa998>.
- [11] A. Phillips, I. Stolarek, B. Kuczkowska, A. Juras, L. Handschuh, J. Piontek, P. Kozłowski, M. Figlerowicz, Comprehensive analysis of microorganisms accompanying human archaeological remains, *GigaScience* 6 (2017) 1–13, <https://doi.org/10.1093/gigascience/gix044>.
- [12] G. Scorrano, S.H. Nielsen, D.L. Vetro, R. Sawafuji, M. Mackie, A. Margaryan, A.K. Fotakis, C. Martínez-Labarga, P.F. Fabbri, M.E. Allentoft, M. Carra, F. Martini, O. Rickards, J.V. Olsen, M.W. Pedersen, E. Cappellini, M. Sikora, Genomic ancestry, diet and microbiomes of Upper Palaeolithic hunter-gatherers from San Teodoro cave, *Commun. Biol.* 5 (2022) 1–13, <https://doi.org/10.1038/s42003-022-04190-2>.
- [13] M.C. Wibowo, Z. Yang, M. Borry, A. Hübner, K.D. Huang, B.T. Tierney, S. Zimmerman, F. Barajas-Olmos, C. Contreras-Cubas, H. García-Ortiz, A. Martínez-Hernández, J.M. Luber, P. Kirstahler, T. Blohm, F.E. Smiley, R. Arnold, S.A. Ballal, S.J. Pamp, J. Russ, F. Maixner, O. Rota-Stabelli, N. Segata, K. Reinhard, L. Orozco, C. Warinner, M. Snow, S. LeBlanc, A.D. Kostic, Reconstruction of ancient microbial genomes from the human gut, *Nature* 594 (2021) 234–239, <https://doi.org/10.1038/s41586-021-03532-0>.
- [14] J.A. Ufnar, S.Y. Wang, J.M. Christiansen, H. Yampara-Iquise, C.A. Carson, R.D. Ellender, Detection of the nifH gene of Methanobrevibacter smithii: a potential tool to identify sewage pollution in recreational waters, *J. Appl. Microbiol.* 101 (2006) 44–52, <https://doi.org/10.1111/j.1365-2672.2006.02989.x>.
- [15] S.M. McQuaig, T.M. Scott, J.O. Lukasik, J.H. Paul, V.J. Harwood, Quantification of human polyomaviruses JC Virus and BK Virus by TaqMan quantitative PCR and comparison to other water quality indicators in water and fecal samples, *Appl. Environ. Microbiol.* 75 (2009) 3379–3388, <https://doi.org/10.1128/AEM.02302-08>.
- [16] V.J. Harwood, M. Brownell, S. Wang, J. Lepo, R.D. Ellender, A. Ajidahun, K.N. Hellein, E. Kennedy, X. Ye, C. Flood, Validation and field testing of library-independent microbial source tracking methods in the Gulf of Mexico, *Water Res.* 43 (2009) 4812–4819, <https://doi.org/10.1016/j.watres.2009.06.029>.
- [17] C. Johnston, J.A. Ufnar, J.F. Griffith, J.A. Gooch, J.R. Stewart, A real-time qPCR assay for the detection of the nifH gene of Methanobrevibacter smithii, a potential indicator of sewage pollution, *J. Appl. Microbiol.* 109 (2010) 1946–1956, <https://doi.org/10.1111/j.1365-2672.2010.04824.x>.
- [18] B. Sercu, L.C. Van De Werfhorst, J.L.S. Murray, P.A. Holden, Terrestrial sources homogenize bacterial water quality during rainfall in two urbanized watersheds in Santa Barbara, CA, *Microb. Ecol.* 62 (2011) 574–583, <https://doi.org/10.1007/s00248-011-9874-z>.
- [19] K.N. Hellein, C. Battie, E. Tauchman, D. Lund, O.A. Oyarzabal, J.E. Lepo, Culture-based indicators of fecal contamination and molecular microbial indicators rarely correlate with Campylobacter spp. in recreational waters, *J. Water Health* 9 (2011) 695–707, <https://doi.org/10.2166/wh.2011.154>.
- [20] W. Ahmed, J.P.S. Sidhu, S. Toze, Evaluation of the nifH gene marker of Methanobrevibacter smithii for the detection of sewage pollution in environmental waters in Southeast Queensland, Australia, *Environ. Sci. Technol.* 46 (2012) 543–550, <https://doi.org/10.1021/es203372u>.
- [21] Z.R. Staley, E. Chase, C. Mitraki, T.L. Crisman, V.J. Harwood, Microbial water quality in freshwater lakes with different land use, *J. Appl. Microbiol.* 115 (2013) 1240–1250, <https://doi.org/10.1111/jam.12312>.
- [22] S.S. Oliveira, M.H.F. Sorgine, K. Bianco, L.H. Pinto, C. Barreto, R.M. Albano, A.M. Cardoso, M.M. Clementino, Detection of human fecal contamination by nifH gene quantification of marine waters in the coastal beaches of Rio de Janeiro, Brazil, *Environ. Sci. Pollut. Res. Int.* 23 (2016) 25210–25217, <https://doi.org/10.1007/s11356-016-7737-3>.
- [23] V. Romanazzi, S. Bonetta, S. Fornasero, M. De Ceglia, G. Gilli, D. Traversi, Assessing Methanobrevibacter smithii and Clostridium difficile as not conventional faecal indicators in effluents of a wastewater treatment plant integrated with sludge anaerobic digestion, *J Environ Manage* 184 (2016) 170–177, <https://doi.org/10.1016/j.jenvman.2016.09.081>.
- [24] C. Lin, T.L. Miller, Phylogenetic analysis of Methanobrevibacter isolated from feces of humans and other animals, *Arch. Microbiol.* 169 (1998) 397–403, <https://doi.org/10.1007/s002030050589>.
- [25] L.C. Skillman, P.N. Evans, C. Strömpl, K.N. Joblin, 16S rDNA directed PCR primers and detection of methanogens in the bovine rumen, *Lett. Appl. Microbiol.* 42 (2006) 222–228, <https://doi.org/10.1111/j.1472-765X.2005.01833.x>.
- [26] M.J. Nicholson, P.N. Evans, K.N. Joblin, Analysis of methanogen diversity in the rumen using temporal temperature gradient gel electrophoresis: identification of uncultured methanogens, *Microb. Ecol.* 54 (2007) 141–150, <https://doi.org/10.1007/s00248-006-9182-1>.
- [27] D. Kušar, G. Avguštin, Molecular profiling and identification of methanogenic archaeal species from rabbit caecum, *FEMS Microbiol. Ecol.* 74 (2010) 623–630, <https://doi.org/10.1111/j.1574-6941.2010.00980.x>.
- [28] M. Zhou, Y.-H. Chung, K.A. Beauchemin, L. Holtshausen, M. Oba, T.A. McAllister, L.L. Guan, Relationship between rumen methanogens and methane production in dairy cows fed diets supplemented with a feed enzyme additive, *J. Appl. Microbiol.* 111 (2011) 1148–1158, <https://doi.org/10.1111/j.1365-2672.2011.05126.x>.
- [29] T.A. McAllister, C.J. Newbold, T.A. McAllister, C.J. Newbold, Redirecting rumen fermentation to reduce methanogenesis, *Aust. J. Exp. Agric.* 48 (2008) 7–13, <https://doi.org/10.1071/EA07218>.
- [30] T.L. Miller, E. Currenti, M.J. Wolin, Anaerobic bioconversion of cellulose by Ruminococcus albus, Methanobrevibacter smithii, and Methanosarcina barkeri, *Appl. Microbiol. Biotechnol.* 54 (2000) 494–498, <https://doi.org/10.1007/s002530000430>.
- [31] D.K. Ngetich, R.C. Bett, C.K. Gachui, F.M. Kibegwa, Diversity of gut methanogens and functional enzymes associated with methane metabolism in smallholder dairy cattle, *Arch. Microbiol.* 204 (2022) 608, <https://doi.org/10.1007/s00203-022-03187-z>.

- [32] C.O. Guindo, B. Davoust, M. Drancourt, G. Grine, Diversity of methanogens in animals' gut, *Microorganisms* 9 (2020) E13, <https://doi.org/10.3390/microorganisms9010013>.
- [33] T. van der Weerden, P. Beukes, C. de Klein, K. Hutchinson, L. Farrell, T. Stormink, A. Romera, D. Dalley, R. Monaghan, D. Chapman, K. Macdonald, R. Dyne, The effects of system changes in grazed dairy farmlands on greenhouse gas emissions, *Animals (Basel)* 8 (2018) 234, <https://doi.org/10.3390/ani8120234>.
- [34] K. Wang, B. Xiong, X. Zhao, Could propionate formation be used to reduce enteric methane emission in ruminants? *Sci. Total Environ.* 855 (2023) 158867 <https://doi.org/10.1016/j.scitotenv.2022.158867>.
- [35] B. Królczewska, E. Pecka-Kielb, J. Bujok, Strategies used to reduce methane emissions from ruminants: controversies and issues, *Agriculture* 13 (2023) 602, <https://doi.org/10.3390/agriculture13030602>.
- [36] A. Ramezani, T.D. Nolin, I.R. Barrows, M.G. Serrano, G.A. Buck, R. Regunathan-Shenk, R.E. West, P.S. Latham, R. Amdur, D.S. Raj, Gut colonization with methanogenic archaea lowers plasma trimethylamine N-oxide concentrations in apolipoprotein e^{-/-} mice, *Sci. Rep.* 8 (2018) 14752, <https://doi.org/10.1038/s41598-018-33018-5>.
- [37] M.R. Aghasadeghi, S.A. Delbaz, S.M. Sadat, S.D. Siadat, M.S. Ardestani, P. Rahimi, A. Bolhassani, R.V. Roudsari, G. Bahramali, F. Motevalli, M. Davari, H. Vakily, A.S. Salmani, M.B. Nobari, Induction of strong and specific humoral and T-helper 1 cellular responses by HBsAg entrapped in the methanobrevibacter smithii archaeosomes, *Avicenna J. Med. Biotechnol. (AJMB)* 6 (2014) 238–245.
- [38] S. Shoaib, F. Karlsson, A. Mardinoglu, I. Nookaew, S. Bordel, J. Nielsen, Understanding the interactions between bacteria in the human gut through metabolic modeling, *Sci. Rep.* 3 (2013) 2532, <https://doi.org/10.1038/srep02532>.
- [39] K. Al, O. Sarr, K. Dunlop, G.B. Gloor, G. Reid, J. Burton, T.R.H. Regnault, Impact of birth weight and postnatal diet on the gut microbiota of young adult Guinea pigs, *PeerJ* 5 (2017) e2840, <https://doi.org/10.7717/peerj.2840>.
- [40] E.M. Walters, R.S. Prather, Advancing swine models for human health and diseases, *Mo. Med.* 110 (2013) 212–215.
- [41] S.R. Kayar, A. Fahلمان, W.C. Lin, W.B. Whitman, Increasing activity of H(2)-metabolizing microbes lowers decompression sickness risk in pigs during H(2) dives, *J. Appl. Physiol.* 91 (2001) 2713–2719, <https://doi.org/10.1152/jappl.2001.91.6.2713>.
- [42] A.H. Togo, G. Grine, S. Khelaifia, C. des Robert, V. Brevaut, A. Caputo, E. Baptiste, M. Bonnet, A. Levasseur, M. Drancourt, M. Million, D. Raoult, Culture of methanogenic archaea from human colostrum and milk, *Sci. Rep.* 9 (2019) 18653, <https://doi.org/10.1038/s41598-019-54759-x>.
- [43] G. Grine, M.A. Boualam, M. Drancourt, Methanobrevibacter smithii, a methanogen consistently colonising the newborn stomach, *Eur. J. Clin. Microbiol. Infect. Dis.* 36 (2017) 2449–2455, <https://doi.org/10.1007/s10096-017-3084-7>.
- [44] S. Khelaifia, D. Raoult, M. Drancourt, A versatile medium for cultivating methanogenic archaea, *PLoS One* 8 (2013) e61563, <https://doi.org/10.1371/journal.pone.0061563>.
- [45] Y. Sereme, C.O. Guindo, A. Filleron, P. Corbeau, T.A. Tran, M. Drancourt, J. Vitte, G. Grine, Meconial Methanobrevibacter smithii suggests intrauterine methanogen colonization in preterm neonates, *Curr Res Microb Sci* 2 (2021) 100034, <https://doi.org/10.1016/j.crmicr.2021.100034>.
- [46] J.M. Rodríguez, K. Murphy, C. Stanton, R.P. Ross, O.I. Kober, N. Juge, E. Avershina, K. Rudi, A. Narbad, M.C. Jenmalm, J.R. Marchesi, M.C. Collado, The composition of the gut microbiota throughout life, with an emphasis on early life, *Microb. Ecol. Health Dis.* 26 (2015), <https://doi.org/10.3402/mehd.v26.26050>.
- [47] G. Grine, H. Drouet, F. Fenollar, F. Bretelle, D. Raoult, M. Drancourt, Detection of Methanobrevibacter smithii in vaginal samples collected from women diagnosed with bacterial vaginosis, *Eur. J. Clin. Microbiol. Infect. Dis.* 38 (2019) 1643–1649, <https://doi.org/10.1007/s10096-019-03592-1>.
- [48] E. Di Profio, V.C. Magenes, G. Fiore, M. Agostinelli, A. La Mendola, M. Acunzo, R. Francavilla, F. Indrio, A. Bosetti, E. D'Auria, E. Borghi, G. Zuccotti, E. Verduci, Special diets in infants and children and impact on gut microbioma, *Nutrients* 14 (2022) 3198, <https://doi.org/10.3390/nu14153198>.
- [49] M.-L. Wernroth, S. Peura, A.M. Hedman, S. Hetty, S. Vicenzi, B. Kennedy, K. Fall, B. Svennblad, E. Andolf, G. Pershagen, J. Theorell-Haglöw, D. Nguyen, S. Sayols-Baixeras, K.F. Dekkers, S. Bertilsson, C. Almqvist, J. Dickved, T. Fall, Development of gut microbiota during the first 2 years of life, *Sci. Rep.* 12 (2022) 9080, <https://doi.org/10.1038/s41598-022-13009-3>.
- [50] Y. Kwon, Y.-S. Cho, Y.-M. Lee, S. Kim, J. Bae, S.-J. Jeong, Changes to gut microbiota following systemic antibiotic administration in infants, *Antibiotics (Basel)* 11 (2022) 470, <https://doi.org/10.3390/antibiotics11040470>.
- [51] C. Bang, A. Schilhabel, K. Weidenbach, A. Kopp, T. Goldmann, T. Gutschmann, R.A. Schmitz, Effects of antimicrobial peptides on methanogenic archaea, *Antimicrob. Agents Chemother.* 56 (2012) 4123–4130, <https://doi.org/10.1128/AAC.00661-12>.
- [52] H.E. Laue, M.O. Coker, J.C. Madan, The developing microbiome from birth to 3 years: the gut-brain axis and neurodevelopmental outcomes, *Front Pediatr* 10 (2022) 815885, <https://doi.org/10.3389/fped.2022.815885>.
- [53] F. Bäckhed, J. Roswall, Y. Peng, Q. Feng, H. Jia, P. Kovatcheva-Datchary, Y. Li, Y. Xia, H. Xie, H. Zhong, M.T. Khan, J. Zhang, J. Li, L. Xiao, J. Al-Aama, D. Zhang, Y.S. Lee, D. Kotowska, C. Colding, V. Tremaroli, Y. Yin, S. Bergman, X. Xu, L. Madsen, K. Kristiansen, J. Dahlgren, J. Wang, Dynamics and stabilization of the human gut microbiome during the first year of life, *Cell Host Microbe* 17 (2015) 690–703, <https://doi.org/10.1016/j.chom.2015.04.004>.
- [54] S. Mason, Some aspects of gastric function in the newborn, *Arch. Dis. Child.* 37 (1962) 387–391.
- [55] B. Dridi, M. Henry, H. Richet, D. Raoult, M. Drancourt, Age-related prevalence of Methanomassiliicoccus luminyensis in the human gut microbiome, *APMIS* 120 (2012) 773–777, <https://doi.org/10.1111/j.1600-0463.2012.02899.x>.
- [56] N. Belay, R. Johnson, B.S. Rajagopal, E.C. de Macario, L. Daniels, Methanogenic bacteria from human dental plaque, *Appl. Environ. Microbiol.* 54 (1988) 600–603.
- [57] G. Grine, E. Terrer, M.A. Boualam, G. Aboudharam, H. Chaudet, R. Ruimy, M. Drancourt, Tobacco-smoking-related prevalence of methanogens in the oral fluid microbiota, *Sci. Rep.* 8 (2018) 9197, <https://doi.org/10.1038/s41598-018-27372-7>.
- [58] E.M.M. Quigley, L.A. Turnberg, pH of the microclimate lining human gastric and duodenal mucosa in vivo: studies in control subjects and in duodenal ulcer patients, *Gastroenterology* 92 (1987) 1876–1884, [https://doi.org/10.1016/0016-5085\(87\)90619-6](https://doi.org/10.1016/0016-5085(87)90619-6).
- [59] E.S. Friedman, K. Bittinger, T.V. Esipova, L. Hou, L. Chau, J. Jiang, C. Mesaros, P.J. Lund, X. Liang, G.A. FitzGerald, M. Goulian, D. Lee, B.A. Garcia, I.A. Blair, S.A. Vinogradov, G.D. Wu, Microbes vs. chemistry in the origin of the anaerobic gut lumen, *Proc Natl Acad Sci U S A* 115 (2018) 4170–4175, <https://doi.org/10.1073/pnas.1718635115>.
- [60] E.M. Bik, P.B. Eckburg, S.R. Gill, K.E. Nelson, E.A. Purdom, F. Francois, G. Perez-Perez, M.J. Blaser, D.A. Relman, Molecular analysis of the bacterial microbiota in the human stomach, *Proc Natl Acad Sci U S A* 103 (2006) 732–737, <https://doi.org/10.1073/pnas.0506655103>.
- [61] G. McCallum, C. Tropini, The gut microbiota and its biogeography, *Nat. Rev. Microbiol.* (2023), <https://doi.org/10.1038/s41579-023-00969-0>.
- [62] D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, J.D. Hardcastle, Measurement of gastrointestinal pH profiles in normal ambulant human subjects, *Gut* 29 (1988) 1035–1041, <https://doi.org/10.1136/gut.29.8.1035>.
- [63] A.M. Seekatz, M.K. Schnitzlein, M.J. Koenigsnecht, J.R. Baker, W.L. Hasler, B.E. Bleske, V.B. Young, D. Sun, Spatial and temporal analysis of the stomach and small-intestinal microbiota in fasted healthy humans, *mSphere* 4 (2019) e00126, <https://doi.org/10.1128/mSphere.00126-19>.
- [64] G. Grine, R. Lotte, D. Chirio, A. Chevalier, D. Raoult, M. Drancourt, R. Ruimy, Co-culture of Methanobrevibacter smithii with enterobacteria during urinary infection, *EBioMedicine* 43 (2019) 333–337, <https://doi.org/10.1016/j.ebiom.2019.04.037>.
- [65] K. Djemai, F. Gouriet, J. Michel, T. Radulesco, M. Drancourt, G. Grine, Methanobrevibacter smithii tonsillar phlegmon: a case report, *New Microbes New Infect* 42 (2021) 100891, <https://doi.org/10.1016/j.nmni.2021.100891>.
- [66] S.G. Pavlostathis, T.L. Miller, M.J. Wolin, Cellulose fermentation by continuous cultures of Ruminococcus albus and Methanobrevibacter smithii, *Appl. Microbiol. Biotechnol.* 33 (1990) 109–116, <https://doi.org/10.1007/BF00170581>.
- [67] T.L. Miller, M.J. Wolin, Methanospira stadtmaniae gen. nov., sp. nov.: a species that forms methane by reducing methanol with hydrogen, *Arch. Microbiol.* 141 (1985) 116–122, <https://doi.org/10.1007/BF00423270>.
- [68] B. Dridi, M.-L. Fardeau, B. Ollivier, D. Raoult, M. Drancourt, Methanomassiliicoccus luminyensis gen. nov., sp. nov., a methanogenic archaeon isolated from human faeces, *Int. J. Syst. Evol. Microbiol.* 62 (2012) 1902–1907, <https://doi.org/10.1099/ijs.0.033712-0>.
- [69] S. Khelaifia, M. Garibaf, C. Robert, D. Raoult, M. Drancourt, Draft genome sequence of a human-associated isolate of methanobrevibacter arboriphilicus, the lowest-g+C-content archaeon, *Genome Announc.* 2 (2014) e01181, <https://doi.org/10.1128/genomeA.01181-13>.

- [70] G. Borrel, H.M.B. Harris, N. Parisot, N. Gaci, W. Tottey, A. Mihajlovski, J. Deane, S. Gribaldo, O. Bardot, E. Peyretailade, P. Peyret, P.W. O'Toole, J.-F. Brugère, Genome sequence of "Candidatus Methanomassiliicoccus intestinalis" issoire-Mx1, a third thermoplasmatales-related methanogenic archaeon from human feces, *Genome Announc.* 1 (2013) e00453, <https://doi.org/10.1128/genomeA.00453-13>.
- [71] G. Borrel, H.M.B. Harris, W. Tottey, A. Mihajlovski, N. Parisot, E. Peyretailade, P. Peyret, S. Gribaldo, P.W. O'Toole, J.-F. Brugère, Genome sequence of "Candidatus Methanomethylphilus alvus" Mx1201, a methanogenic archaeon from the human gut belonging to a seventh order of methanogens, *J. Bacteriol.* 194 (2012) 6944–6945, <https://doi.org/10.1128/JB.01867-12>.
- [72] B.S. Samuel, E.E. Hansen, J.K. Manchester, P.M. Coutinho, B. Henriksat, R. Fulton, P. Latreille, K. Kim, R.K. Wilson, J.I. Gordon, Genomic and metabolic adaptations of *Methanobrevibacter smithii* to the human gut, *Proc. Natl. Acad. Sci. USA* 104 (2007) 10643–10648, <https://doi.org/10.1073/pnas.0704189104>.
- [73] J.L. Catlett, S. Carr, M. Cashman, M.D. Smith, M. Walter, Z. Sakkaff, C. Kelley, M. Pierobon, M.B. Cohen, N.R. Buan, Metabolic synergy between human symbionts *Bacteroides* and *Methanobrevibacter*, *Microbiol. Spectr.* 10 (2022) e0106722, <https://doi.org/10.1128/spectrum.01067-22>.
- [74] S.M. Murga-Garrido, Y.C. Orbe-Orihuela, C.E. Díaz-Benítez, A.C. Castañeda-Márquez, F. Cornejo-Granados, A. Ochoa-Leyva, A. Sanchez-Flores, M. Cruz, A. I. Burguete-García, A. Lagunas-Martínez, Alterations of the gut microbiome associated to methane metabolism in Mexican children with obesity, *Children* 9 (2022) 148, <https://doi.org/10.3390/children9020148>.
- [75] Y. Hassani, F. Brégeon, G. Aboudharam, M. Drancourt, G. Grine, Detection of *Methanobrevibacter smithii* and *Methanobrevibacter oralis* in lower respiratory tract microbiota, *Microorganisms* 8 (2020) E1866, <https://doi.org/10.3390/microorganisms8121866>.
- [76] P.S. Pannaraj, F. Li, C. Cerini, J.M. Bender, S. Yang, A. Rollie, H. Adisetiyo, S. Zabih, P.J. Lincez, K. Bittinger, A. Bailey, F.D. Bushman, J.W. Sleasman, G. M. Aldrovandi, Association between breast milk bacterial communities and establishment and development of the infant gut microbiome, *JAMA Pediatr.* 171 (2017) 647–654, <https://doi.org/10.1001/jamapediatrics.2017.0378>.
- [77] V. Martín, A. Maldonado-Barragán, L. Moles, M. Rodríguez-Baños, R.D. Campo, L. Fernández, J.M. Rodríguez, E. Jiménez, Sharing of bacterial strains between breast milk and infant feces, *J Hum Lact* 28 (2012) 36–44, <https://doi.org/10.1177/0890334411424729>.
- [78] P. Cheeseman, A. Toms-Wood, R.S. Wolfe, Isolation and properties of a fluorescent compound, factor 420, from *Methanobacterium* strain M.o.H, *J. Bacteriol.* 112 (1972) 527–531, <https://doi.org/10.1128/jb.112.1.527-531.1972>.
- [79] M.E. Jennings, N. Chia, L.A. Boardman, W.W. Metcalf, Draft genome sequence of *Methanobrevibacter smithii* isolate WWM1085, obtained from a human stool sample, *Genome Announc.* 5 (2017) e01055, <https://doi.org/10.1128/genomeA.01055-17>.
- [80] J. Lambrecht, N. Cichocki, T. Hübschmann, C. Koch, H. Harms, S. Müller, Flow cytometric quantification, sorting and sequencing of methanogenic archaea based on F420 autofluorescence, *Microb. Cell Factories* 16 (2017) 180, <https://doi.org/10.1186/s12934-017-0793-7>.
- [81] A.M. Oliveira Paiva, A.H. Friggen, R. Douwes, B. Wittekoek, W.K. Smits, Practical observations on the use of fluorescent reporter systems in *Clostridioides difficile*, *Antonie Leeuwenhoek* 115 (2022) 297–323, <https://doi.org/10.1007/s10482-021-01691-8>.
- [82] Y. Bae, T. Ito, T. Iida, K. Uchida, M. Sekine, Y. Nakajima, J. Kumagai, T. Yokoyama, H. Kawachi, T. Akashi, Y. Eishi, Intracellular *Propionibacterium acnes* infection in glandular epithelium and stromal macrophages of the prostate with or without cancer, *PLoS One* 9 (2014) e90324, <https://doi.org/10.1371/journal.pone.0090324>.
- [83] V. Pillioli, C.O. Guindo, E. Terrer, G. Aboudharam, M. Drancourt, G. Grine, Culturing clinical *Methanobrevibacter smithii* using GG medium in a minimal anaerobe atmosphere, *J. Microbiol. Methods* 207 (2023) 106704, <https://doi.org/10.1016/j.mimet.2023.106704>.
- [84] E. Conway de Macario, M.J. Wolin, A.J.L. Macario, rD, *Science* 214 (1981) 74–75, <https://doi.org/10.1126/science.6792708>.
- [85] A. Moter, U.B. Göbel, Fluorescence in situ hybridization (FISH) for direct visualization of microorganisms, *J. Microbiol. Methods* 41 (2000) 85–112, [https://doi.org/10.1016/S0167-7012\(00\)00152-4](https://doi.org/10.1016/S0167-7012(00)00152-4).
- [86] L. Raskin, J.M. Stromley, B.E. Rittmann, D.A. Stahl, Group-specific 16S rRNA hybridization probes to describe natural communities of methanogens, *Appl. Environ. Microbiol.* 60 (1994) 1232–1240.
- [87] J.M. Ridlon, S.E. McGarr, P.B. Hylemon, Development of methods for the detection and quantification of 7 α -dehydroxylating clostridia, *Desulfovibrio vulgaris*, *Methanobrevibacter smithii*, and *Lactobacillus plantarum* in human feces, *Clin. Chim. Acta* 357 (2005) 55–64, <https://doi.org/10.1016/j.cccn.2005.02.004>.
- [88] E. Donatin, M. Drancourt, Optimized microbial DNA extraction from diarrheic stools, *BMC Res. Notes* 5 (2012) 702, <https://doi.org/10.1186/1756-0500-5-702>.
- [89] E.M. Kulik, H. Sandmeier, K. Hinni, J. Meyer, Identification of archaeal rDNA from subgingival dental plaque by PCR amplification and sequence analysis, *FEMS Microbiol. Lett.* 196 (2001) 129–133, <https://doi.org/10.1111/j.1574-6968.2001.tb10553.x>.
- [90] P.D. Scanlan, F. Shanahan, J.R. Marchesi, Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis, *BMC Microbiol.* 8 (2008) 79, <https://doi.org/10.1186/1471-2180-8-79>.
- [91] S. Khelaifia, P.-Y. Ramonet, M. Bedotto Buffet, M. Drancourt, A semi-automated protocol for Archaea DNA extraction from stools, *BMC Res. Notes* 6 (2013) 186, <https://doi.org/10.1186/1756-0500-6-186>.
- [92] T. Thomas, J. Gilbert, F. Meyer, Metagenomics - a guide from sampling to data analysis, *Microb Inform Exp* 2 (2012) 3, <https://doi.org/10.1186/2042-5783-2-3>.
- [93] P.B. Eckburg, E.M. Bik, C.N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S.R. Gill, K.E. Nelson, D.A. Relman, Diversity of the human intestinal microbial flora, *Science* 308 (2005) 1635–1638, <https://doi.org/10.1126/science.1110591>.
- [94] S.R. Gill, M. Pop, R.T. Deboy, P.B. Eckburg, P.J. Turnbaugh, B.S. Samuel, J.I. Gordon, D.A. Relman, C.M. Fraser-Liggett, K.E. Nelson, Metagenomic analysis of the human distal gut microbiome, *Science* 312 (2006) 1355–1359, <https://doi.org/10.1126/science.1124234>.
- [95] C. Palmer, E.M. Bik, D.B. DiGiulio, D.A. Relman, P.O. Brown, Development of the human infant intestinal microbiota, *PLoS Biol.* 5 (2007) e177, <https://doi.org/10.1371/journal.pbio.0050177>.
- [96] Y.-D. Nam, H.-W. Chang, K.-H. Kim, S.W. Roh, M.-S. Kim, M.-J. Jung, S.-W. Lee, J.-Y. Kim, J.-H. Yoon, J.-W. Bae, Bacterial, archaeal, and eukaryal diversity in the intestines of Korean people, *J. Microbiol.* 46 (2008) 491–501, <https://doi.org/10.1007/s12275-008-0199-7>.
- [97] J. Qin, R. Li, J. Raes, M. Arumugam, K.S. Burgdorf, C. Manichanh, T. Nielsen, N. Pons, F. Levenez, T. Yamada, D.R. Mende, J. Li, J. Xu, S. Li, D. Li, J. Cao, B. Wang, H. Liang, H. Zheng, Y. Xie, J. Tap, P. Lepage, M. Bertalan, J.-M. Batto, T. Hansen, D. Le Paslier, A. Linneberg, H.B. Nielsen, E. Pelletier, P. Renault, T. Sicheritz-Ponten, K. Turner, H. Zhu, C. Yu, S. Li, M. Jian, Y. Zhou, Y. Li, X. Zhang, S. Li, N. Qin, H. Yang, J. Wang, S. Brunak, J. Doré, F. Guarner, K. Kristiansen, O. Pedersen, J. Parkhill, J. Weissenbach, P. Bork, S.D. Ehrlich, J. Wang, A human gut microbial gene catalogue established by metagenomic sequencing, *Nature* 464 (2010) 59–65, <https://doi.org/10.1038/nature08821>.
- [98] J. Li, H. Jia, X. Cai, H. Zhong, Q. Feng, S. Sunagawa, M. Arumugam, J.R. Kultima, E. Prifti, T. Nielsen, A.S. Juncker, C. Manichanh, B. Chen, W. Zhang, F. Levenez, J. Wang, X. Xu, L. Xiao, S. Liang, D. Zhang, Z. Zhang, W. Chen, H. Zhao, J.Y. Al-Aama, S. Edris, H. Yang, J. Wang, T. Hansen, H.B. Nielsen, S. Brunak, K. Kristiansen, F. Guarner, O. Pedersen, J. Doré, S.D. Ehrlich, P. Bork, J. Wang, An integrated catalog of reference genes in the human gut microbiome, *Nat. Biotechnol.* 32 (2014) 834–841, <https://doi.org/10.1038/nbt.2942>.
- [99] R.K. Thauer, K. Jungermann, K. Decker, Energy conservation in chemotrophic anaerobic bacteria, *Bacteriol. Rev.* 41 (1977) 100–180, <https://doi.org/10.1128/br.41.1.100-180.1977>.
- [100] S. Stolyar, S. Van Dien, K.L. Hillesland, N. Pinel, T.J. Lie, J.A. Leigh, D.A. Stahl, Metabolic modeling of a mutualistic microbial community, *Mol. Syst. Biol.* 3 (2007) 92, <https://doi.org/10.1038/msb4100131>.
- [101] J.R. Zaneveld, C. Lozupone, J.I. Gordon, R. Knight, Ribosomal RNA diversity predicts genome diversity in gut bacteria and their relatives, *Nucleic Acids Res.* 38 (2010) 3869–3879, <https://doi.org/10.1093/nar/gkq066>.
- [102] S. Shoaie, P. Ghaffari, P. Kovatcheva-Datchary, A. Mardinoglu, P. Sen, E. Pujos-Guillot, T. de Wouters, C. Juste, S. Rizkalla, J. Chilloux, L. Hoyle, J. K. Nicholson, J. Dore, M.E. Dumas, K. Clement, F. Bäckhed, J. Nielsen, Quantifying diet-induced metabolic changes of the human gut microbiome, *Cell Metabol.* 22 (2015) 320–331, <https://doi.org/10.1016/j.cmet.2015.07.001>.

- [103] N. Belay, L. Daniels, Production of ethane, ethylene, and acetylene from halogenated hydrocarbons by methanogenic bacteria, *Appl. Environ. Microbiol.* 53 (1987) 1604–1610, <https://doi.org/10.1128/aem.53.7.1604-1610.1987>.
- [104] N. Belay, B. Mukhopadhyay, E. Conway de Macario, R. Galask, L. Daniels, Methanogenic bacteria in human vaginal samples, *J. Clin. Microbiol.* 28 (1990) 1666–1668.
- [105] S. Khelaifia, J.-C. Lagier, V.D. Nkanga, E. Guilhot, M. Drancourt, D. Raoult, Aerobic culture of methanogenic archaea without an external source of hydrogen, *Eur. J. Clin. Microbiol. Infect. Dis.* 35 (2016) 985–991, <https://doi.org/10.1007/s10096-016-2627-7>.
- [106] P. Krader, D. Emerson, Identification of archaea and some extremophilic bacteria using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, *Extremophiles* 8 (2004) 259–268, <https://doi.org/10.1007/s00792-004-0382-7>.
- [107] B. Dridi, D. Raoult, M. Drancourt, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of Archaea: towards the universal identification of living organisms, *APMIS* 120 (2012) 85–91, <https://doi.org/10.1111/j.1600-0463.2011.02833.x>.
- [108] C.O. Guindo, L. Amir, C. Couderc, M. Drancourt, G. Grine, Rapid identification of clinically interesting methanogens using an improved MALDI-TOF-MS assay, *Access Microbiol* 4 (2022), <https://doi.org/10.1099/acmi.0.000372> acmi000372.
- [109] S.I. Traore, S. Khelaifia, N. Armstrong, J.C. Lagier, D. Raoult, Isolation and culture of Methanobrevibacter smithii by co-culture with hydrogen-producing bacteria on agar plates, *Clin. Microbiol. Infect.* 25 (2019) 1561.e1–1561.e5, <https://doi.org/10.1016/j.cmi.2019.04.008>.
- [110] Y. Hassani, Introduction à la nanoarchéologie clinique, These de doctorat, Aix-Marseille, 2022. <https://www.theses.fr/2022AIXM0621>. (Accessed 18 September 2023).
- [111] Y. Hassani, J. Saad, E. Terrer, G. Aboudharam, B. Giancarlo, F. Silvestri, D. Raoult, M. Drancourt, G. Grine, Introducing clinical nanorachaeology: isolation by co-culture of Nanopusillus massiliensis sp. nov, *Curr Res Microb Sci* 3 (2022) 100100, <https://doi.org/10.1016/j.crmicr.2021.100100>.
- [112] B.-C. Kim, H. Jeong, Complete genome sequence of methanobrevibacter smithii strain KB11, isolated from a Korean fecal sample, *Genome Announc.* 6 (2018) e00038, <https://doi.org/10.1128/genomeA.00038-18>.
- [113] V.D. Nkanga, H.T.T. Huynh, G. Aboudharam, R. Ruimy, M. Drancourt, Diversity of human-associated Methanobrevibacter smithii isolates revealed by multispacer sequence typing, *Curr. Microbiol.* 70 (2015) 810–815, <https://doi.org/10.1007/s00284-015-0787-9>.
- [114] E. Hartmann, H. König, Comparison of the biosynthesis of the methanobacterial pseudomurein and the eubacterial murein, *Naturwissenschaften* 77 (1990) 472–475, <https://doi.org/10.1007/BF01135923>.
- [115] V. Lupo, C. Roomans, E. Royen, L. Ongena, O. Jacquemin, F. Kerff, D. Baurain, Origin and evolution of pseudomurein biosynthetic gene clusters, 11.30.518518, <https://doi.org/10.1101/2022.11.30.518518>, 2022.
- [116] H. König, E. Hartmann, U. Kärcher, Pathways and principles of the biosynthesis of methanobacterial cell wall polymers, *Syst. Appl. Microbiol.* 16 (1993) 510–517, [https://doi.org/10.1016/S0723-2020\(11\)80320-6](https://doi.org/10.1016/S0723-2020(11)80320-6).
- [117] D.-J. Scheffers, M.G. Pinho, Bacterial cell wall synthesis: new insights from localization studies, *Microbiol. Mol. Biol. Rev.* 69 (2005) 585–607, <https://doi.org/10.1128/MMBR.69.4.585-607.2005>.
- [118] H. Claus, H. König, Cell envelopes of methanogens, in: H. König, H. Claus, A. Varma (Eds.), *Prokaryotic Cell Wall Compounds: Structure and Biochemistry*, Springer, Berlin, Heidelberg, 2010, pp. 231–251, https://doi.org/10.1007/978-3-642-05062-6_7.
- [119] G.D. Sprott, J. Brisson, C.J. Dicaire, A.K. Pelletier, L.A. Deschatelets, L. Krishnan, G.B. Patel, A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomes, *Biochim. Biophys. Acta* 1440 (1999) 275–288, [https://doi.org/10.1016/S1388-1981\(99\)00130-4](https://doi.org/10.1016/S1388-1981(99)00130-4).
- [120] M.F. Siliakus, J. van der Oost, S.W.M. Kengen, Adaptations of archaeal and bacterial membranes to variations in temperature, pH and pressure, *Extremophiles* 21 (2017) 651–670, <https://doi.org/10.1007/s00792-017-0939-x>.
- [121] T. Bauersachs, K. Weidenbach, R.A. Schmitz, L. Schwark, Distribution of glycerol ether lipids in halophilic, methanogenic and hyperthermophilic archaea, *Org. Geochem.* 83–84 (2015) 101–108, <https://doi.org/10.1016/j.orggeochem.2015.03.009>.
- [122] H.L. Dermoumi, R.A. Ansorg, Isolation and antimicrobial susceptibility testing of fecal strains of the archaeon Methanobrevibacter smithii, *Chemotherapy* 47 (2001) 177–183, <https://doi.org/10.1159/000063219>.
- [123] B. Dridi, M.-L. Fardeau, B. Ollivier, D. Raoult, M. Drancourt, The antimicrobial resistance pattern of cultured human methanogens reflects the unique phylogenetic position of archaea, *J. Antimicrob. Chemother.* 66 (2011) 2038–2044, <https://doi.org/10.1093/jac/dkr251>.
- [124] K. Djemai, F. Gouriet, I. Sieleznoff, D. Mege, M. Drancourt, G. Grine, Detection of methanogens in peri-appendicular abscesses: report of four cases, *Anaerobe* 72 (2021) 102470, <https://doi.org/10.1016/j.anaerobe.2021.102470>.
- [125] K.R. Farley, W.W. Metcalf, The streptothricin acetyltransferase (sat) gene as a positive selectable marker for methanogenic archaea, *FEMS Microbiol. Lett.* 366 (2019) fnz216, <https://doi.org/10.1093/femsle/fnz216>.
- [126] V. Demonfort Nkanga, N. Armstrong, M. Drancourt, In vitro susceptibility of cultured human methanogens to lovastatin, *Int. J. Antimicrob. Agents* 49 (2017) 176–182, <https://doi.org/10.1016/j.ijantimicag.2016.09.026>.
- [127] S. Khelaifia, J.M. Brunel, J.B. Michel, M. Drancourt, In-vitro archaeocidal activity of biocides against human-associated archaea, *PLoS One* 8 (2013) e62738, <https://doi.org/10.1371/journal.pone.0062738>.
- [128] T.P.N. Bui, H.A. Schols, M. Jonathan, A.J.M. Stams, W.M. de Vos, C.M. Plugge, Mutual metabolic interactions in Co-cultures of the intestinal Anaerostipes rhamnosivorans with an acetogen, methanogen, or pectin-degrader affecting butyrate production, *Front. Microbiol.* 10 (2019) 2449, <https://doi.org/10.3389/fmicb.2019.02449>.
- [129] A. Ruaud, S. Esquivel-Elizondo, J. de la Cuesta-Zuluaga, J.L. Waters, L.T. Angenent, N.D. Youngblut, R.E. Ley, Syntrophy via interspecies H₂ transfer between Christensenella and methanobrevibacter underlies their global cooccurrence in the human gut, *mBio* 11 (2020) e03235, <https://doi.org/10.1128/mBio.03235-19>.
- [130] W. Tottey, N. Gaci, G. Borrel, M. Alric, P.W. O'Toole, J.-F. Brugère, In-vitro model for studying methanogens in human gut microbiota, *Anaerobe* 34 (2015) 50–52, <https://doi.org/10.1016/j.anaerobe.2015.04.009>.
- [131] G.-H. Bai, S.-C. Lin, Y.-H. Hsu, S.-Y. Chen, The human virome: viral metagenomics, relations with human diseases, and therapeutic applications, *Viruses* 14 (2022) 278, <https://doi.org/10.3390/v14020278>.
- [132] Z. Cao, N. Sugimura, E. Burgermeister, M.P. Ebert, T. Zuo, P. Lan, The gut virome: a new microbiome component in health and disease, *EBioMedicine* 81 (2022), <https://doi.org/10.1016/j.ebiom.2022.104113>.
- [133] R. Li, Y. Wang, H. Hu, Y. Tan, Y. Ma, Metagenomic analysis reveals unexplored diversity of archaeal virome in the human gut, *Nat. Commun.* 13 (2022) 7978, <https://doi.org/10.1038/s41467-022-35735-y>.
- [134] S. Medvedeva, G. Borrel, M. Krupovic, S. Gribaldo, A global virome of methanogenic archaea highlights novel diversity and adaptations to the gut environmen. <https://doi.org/10.21203/rs.3.rs-2539466/v1>, 2023.
- [135] S. Medvedeva, G. Borrel, M. Krupovic, S. Gribaldo, A compendium of viruses from methanogenic archaea reveals their diversity and adaptations to the gut environment, *Nat Microbiol* (2023) 1–13, <https://doi.org/10.1038/s41564-023-01485-w>.
- [136] C.S. Stewart, A.J. Richardson, Enhanced resistance of anaerobic rumen fungi to the ionophores monensin and lasalocid in the presence of methanogenic bacteria, *J. Appl. Bacteriol.* 66 (1989) 85–93, <https://doi.org/10.1111/j.1365-2672.1989.tb02458.x>.
- [137] E. Cansunar, A.J. Richardson, G. Wallace, C.S. Stewart, Effect of coumarin on glucose uptake by anaerobic rumen fungi in the presence and absence of Methanobrevibacter smithii, *FEMS Microbiol. Lett.* 58 (1990) 157–160, <https://doi.org/10.1111/j.1574-6968.1990.tb13970.x>.
- [138] K.N. Joblin, G.E. Naylor, A.G. Williams, Effect of methanobrevibacter smithii on xylanolytic activity of anaerobic ruminal fungi, *Appl. Environ. Microbiol.* 56 (1990) 2287–2295, <https://doi.org/10.1128/aem.56.8.2287-2295.1990>.
- [139] F.D. Marvin-Sikkema, A.J. Richardson, C.S. Stewart, J.C. Gottschal, R.A. Prins, Influence of hydrogen-consuming bacteria on cellulose degradation by anaerobic fungi, *Appl. Environ. Microbiol.* 56 (1990) 3793–3797, <https://doi.org/10.1128/aem.56.12.3793-3797.1990>.
- [140] K.N. Joblin, H. Matsui, G.E. Naylor, K. Ushida, Degradation of fresh ryegrass by methanogenic co-cultures of ruminal fungi grown in the presence or absence of Fibrobacter succinogenes, *Curr. Microbiol.* 45 (2002) 46–53, <https://doi.org/10.1007/s00284-001-0078-5>.

- [141] M. Faseleh Jahromi, J.B. Liang, Y.W. Ho, R. Mohamad, Y.M. Goh, P. Shokryazdan, J. Chin, Lovastatin in *Aspergillus terreus*: fermented rice straw extracts interferes with methane production and gene expression in *Methanobrevibacter smithii*, *BioMed Res. Int.* 2013 (2013) 604721, <https://doi.org/10.1155/2013/604721>.
- [142] C. Bang, K. Weidenbach, T. Gutsmann, H. Heine, R.A. Schmitz, The intestinal archaea *Methanosphaera stadtmanae* and *Methanobrevibacter smithii* activate human dendritic cells, *PLoS One* 9 (2014) e99411, <https://doi.org/10.1371/journal.pone.0099411>.
- [143] C. Bang, T. Vierbuchen, T. Gutsmann, H. Heine, R.A. Schmitz, Immunogenic properties of the human gut-associated archaeon *Methanomassiliicoccus luminyensis* and its susceptibility to antimicrobial peptides, *PLoS One* 12 (2017) e0185919, <https://doi.org/10.1371/journal.pone.0185919>.
- [144] L. Krishnan, G.D. Sprott, Archaeosome adjuvants: immunological capabilities and mechanism(s) of action, *Vaccine* 26 (2008) 2043–2055, <https://doi.org/10.1016/j.vaccine.2008.02.026>.
- [145] G.D. Sprott, D.L. Tolson, G.B. Patel, Archaeosomes as novel antigen delivery systems, *FEMS Microbiol. Lett.* 154 (1997) 17–22, <https://doi.org/10.1111/j.1574-6968.1997.tb12618.x>.
- [146] K. Triantafyllou, C. Chang, M. Pimentel, Methanogens, methane and gastrointestinal motility, *J Neurogastroenterol Motil* 20 (2014) 31–40, <https://doi.org/10.5056/jnm.2014.20.1.31>.
- [147] M. Pimentel, A.G. Mayer, S. Park, E.J. Chow, A. Hasan, Y. Kong, Methane production during lactulose breath test is associated with gastrointestinal disease presentation, *Dig. Dis. Sci.* 48 (2003) 86–92, <https://doi.org/10.1023/a:1021738515885>.
- [148] R. Mathur, G.M. Barlow, Obesity and the microbiome, *Expert Rev Gastroenterol Hepatol* 9 (2015) 1087–1099, <https://doi.org/10.1586/17474124.2015.1051029>.
- [149] D. Raoult, M. Drancourt, F. Fenollar, G. Grine, Méthode de diagnostic d'une vaginose bactérienne par détection de *Methanobrevibacter smithii*, WO2019122545A1, <https://patents.google.com/patent/WO2019122545A1/fr#patentCitations>, 2019. (Accessed 8 December 2023).
- [150] M. Million, M. Tidjani Alou, S. Khelaifia, D. Bachar, J.-C. Lagier, N. Dione, S. Brah, P. Hugon, V. Lombard, F. Armougom, J. Fromonot, C. Robert, C. Michelle, A. Diallo, A. Fabre, R. Guieu, C. Sokhna, B. Henrissat, P. Parola, D. Raoult, Increased gut redox and depletion of anaerobic and methanogenic prokaryotes in severe acute malnutrition, *Sci. Rep.* 6 (2016) 26051, <https://doi.org/10.1038/srep26051>.
- [151] M. Drancourt, V.D. Nkamga, N.A. Lakhe, J.-M. Régis, H. Dufour, P.-E. Fournier, Y. Bechah, W.M. Scheld, D. Raoult, Evidence of archaeal methanogens in brain abscess, *Clin. Infect. Dis.* 65 (2017) 1–5, <https://doi.org/10.1093/cid/cix286>.
- [152] H.T.T. Huynh, M. Pignoly, V.D. Nkamga, M. Drancourt, G. Aboudharam, The repertoire of archaea cultivated from severe periodontitis, *PLoS One* 10 (2015) e0121565, <https://doi.org/10.1371/journal.pone.0121565>.
- [153] Y. Luo, A.-D.G. Wright, Y. Li, H. Li, Q. Yang, L. Luo, M. Yang, Diversity of methanogens in the hindgut of captive white rhinoceroses, *Ceratotherium simum*, *BMC Microbiol.* 13 (2013) 207, <https://doi.org/10.1186/1471-2180-13-207>.
- [154] N.E.H. Mathlouthi, I. Belguith, M. Yengui, H. Oumarou Hama, J.-C. Lagier, L. Ammar Keskes, G. Grine, R. Gdoura, The archaeome's role in colorectal cancer: unveiling the DPANN group and investigating archaeal functional signatures, *Microorganisms* 11 (2023) 2742, <https://doi.org/10.3390/microorganisms11112742>.
- [155] A. Gupta, D.B. Dhakan, A. Maji, R. Saxena, V.P. P K, S. Mahajan, J. Pulikkan, J. Kurian, A.M. Gomez, J. Scaria, K.R. Amato, A.K. Sharma, V.K. Sharma, Association of flavonifractor plautii, a flavonoid-degrading bacterium, with the gut microbiome of colorectal cancer patients in India, *mSystems* 4 (2019) e00438, <https://doi.org/10.1128/mSystems.00438-19>.
- [156] O.O. Coker, W.K.K. Wu, S.H. Wong, J.J.Y. Sung, J. Yu, Altered gut archaea composition and interaction with bacteria are associated with colorectal cancer, *Gastroenterology* 159 (2020) 1459–1470.e5, <https://doi.org/10.1053/j.gastro.2020.06.042>.
- [157] C. Bang, R.A. Schmitz, Archaea: forgotten players in the microbiome, *Emerg Top Life Sci* 2 (2018) 459–468, <https://doi.org/10.1042/ETLS20180035>.
- [158] E. Sogodogo, M. Drancourt, G. Grine, Methanogens as emerging pathogens in anaerobic abscesses, *Eur. J. Clin. Microbiol. Infect. Dis.* 38 (2019) 811–818, <https://doi.org/10.1007/s10096-019-03510-5>.
- [159] G. Borrel, J.-F. Brugère, S. Gribaldo, R.A. Schmitz, C. Moissl-Eichinger, The host-associated archaeome, *Nat. Rev. Microbiol.* 18 (2020) 622–636, <https://doi.org/10.1038/s41579-020-0407-y>.
- [160] C.O. Guindo, M. Drancourt, G. Grine, Digestive tract methanodrome: physiological roles of human microbiota-associated methanogens, *Microb. Pathog.* 149 (2020) 104425, <https://doi.org/10.1016/j.micpath.2020.104425>.
- [161] C.M. Chibani, A. Mahnert, G. Borrel, A. Almeida, A. Werner, J.-F. Brugère, S. Gribaldo, R.D. Finn, R.A. Schmitz, C. Moissl-Eichinger, A catalogue of 1,167 genomes from the human gut archaeome, *Nat Microbiol* 7 (2022) 48–61, <https://doi.org/10.1038/s41564-021-01020-9>.
- [162] Z. Lyu, N. Shao, T. Akinyemi, W.B. Whitman, Methanogenesis, *Curr. Biol.* 28 (2018) R727–R732, <https://doi.org/10.1016/j.cub.2018.05.021>.
- [163] A. Mihajlovski, M. Alric, J.-F. Brugère, A putative new order of methanogenic Archaea inhabiting the human gut, as revealed by molecular analyses of the *mcrA* gene, *Res. Microbiol.* 159 (2008) 516–521, <https://doi.org/10.1016/j.resmic.2008.06.007>.
- [164] T.L. Miller, M.J. Wolin, Fermentation by the human large intestine microbial community in an in vitro semicontinuous culture system, *Appl. Environ. Microbiol.* 42 (1981) 400–407, <https://doi.org/10.1128/aem.42.3.400-407.1981>.
- [165] M. Kimura, A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences, *J. Mol. Evol.* 16 (1980) 111–120, <https://doi.org/10.1007/BF01731581>.
- [166] S. Kumar, G. Stecher, K. Tamura, MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets, *Mol. Biol. Evol.* 33 (2016) 1870–1874, <https://doi.org/10.1093/molbev/msw054>.